嗜铬细胞瘤新诊断方法的建立以及SGL-3、SGL-1治疗心力衰竭的药理学研究
|
摘要
背景嗜铬细胞瘤是一种多发于肾上腺髓质的罕见肿瘤,如不能及时诊断治疗常会导致严重的突发心血管疾病甚至死亡。传统的嗜铬细胞瘤生化诊断方法均存在准确性不高等问题,变肾上腺素类物质(包括变肾上腺素和变去甲肾上腺素)是目前国际公认的嗜铬细胞瘤的首选检测指标。而据了解,国内目前还没有建立24小时尿变肾上腺素类物质的检测方法。本研究的目的是运用高效液相色谱仪建立24h尿变肾上腺素类物质的检测方法,从可靠性和准确性等方面考察此方法在嗜铬细胞瘤诊断中的应用价值,确立其诊断标准和正常值范围,并通过与儿茶酚胺检测结果的比较验证变肾上腺素类物质在嗜铬细胞瘤诊断中的优越性。
方法首先通过加热使结合型变肾上腺素类物质转化为游离型变肾上腺素类物质,然后使用固相萃取柱进行提取,蒸干重溶后采用高效液相色谱-电化学法进行检测。通过测定仪器变异、批内变异、批间变异和回收率来考察方法的稳定性。然后用此方法对324例高血压非嗜铬细胞瘤患者(对照组)和7例嗜铬细胞瘤患者(病例组)进行了变肾上腺素类物质的检查,运用受试者工作曲线确定诊断标准,用百分位法确定正常值范围。同时对部分病例的血浆儿茶酚胺或24h尿儿茶酚胺进行了检测。
结果①变肾上腺素、变去甲肾上腺素的出峰时间均不超过10分钟;②变肾上腺素的仪器变异、组内变异、批间变异和回收率分别为2.3%、5.5%、5.1%、93.4%;变去甲肾上腺素的仪器变异、组内变异、批间变异和回收率分别为1.9%、4.8%、4.7%、87.9%;③对照组的变肾上腺素检测值为152±114μg/24h,变去甲肾上腺素检测值为294±267μg/24h,病例组的变肾上腺素检测值为1426±1956μg/24h,变去甲肾上腺素检测值为4376±2591μg/24h;④变肾上腺素的诊断标准为415μg/24h,99%正常值范围上限为419μg/24h,变去甲肾上腺素的诊断标准为1464μ∥24h,99%正常值范围上限为1184μg/24h;⑤变肾上腺素诊断的灵敏度为71.4%,特异度为98.8%,变去甲肾上腺素诊断的灵敏度为100%,特异度为100%,血浆去甲肾上腺素诊断的灵敏度为71.4%,特异度为79.0%,24小时尿去甲肾上腺素诊断的灵敏度为100%,特异度为82.4%。
结论本研究建立了快速、稳定、准确的24小时尿变肾上腺素类物质的检测方法,并在国内首次确立了其诊断标准和正常值范围;相比血浆、尿儿茶酚胺等检测指标,变肾上腺素类物质是目前临床检验嗜铬细胞瘤的最佳指标。
背景在过去的几十年中,尽管人们对充血性心力衰竭的认识逐渐加深,治疗手段和治疗效果也有了明显改善,但心衰患者的发病率和死亡率依然居高不下,开发新的心衰治疗药物仍具有重要而迫切的临床意义。SGL-3是一个传统中药组方,经长期临床应用证明对心力衰竭具有显著的改善作用。本研究的目的之一即通过体内、体外实验验证SGL-3对心力衰竭的治疗效果,并初步探讨其作用机制。SGL-1是一个黄酮类化合物单体,经前期实验证明具有强抗氧化性,而在心力衰竭尤其是过量应用抗癌药物阿霉素导致的心脏毒性中,活性氧的产生是最重要的作用机理,因此,本研究的另一目的是通过体外实验验证SGL-1对阿霉素所致心脏毒性的改善作用,为进一步研究SGL-1在治疗心力衰竭中的应用和机理打下基础。
方法①SGL-3体外实验。采用Angiotensin-Ⅱ(1μmol/L)刺激原代培养的乳鼠心肌细胞引起心肌细胞的肥大,通过H~3掺入实验和鬼笔环肽染色观察SGL-3(10μg/mL)对心肌细胞肥大的抑制作用。②SGL-3体内试验。采用20周龄雄性Wistar大鼠,对大鼠进行腹主动脉缩窄手术(AAC)或假手术,20周后,通过超声心动图检测确定术后大鼠出现的心脏功能异常。之后将动物分组,灌胃给药,SGL-3的给药浓度为:150 mg·kg~(-1)·d~(-1)、500 mg·kg~(-1)·d~(-1)和1,500 mg·kg~(-1)·d~(-1),同时设置对照组,即卡托普利(270 mg·kg~(-1)·d~(-1))与倍他乐克(1,800 mg·kg~(-1)·d~(-1))合用组,给药18周。然后使用多导生理仪和超声心动图检测不同组大鼠的射血分数(EF)等心脏血流动力学和形态学参数,采用苏木素—伊红染色、masson染色及天狼猩红染色进行了病理学检查,并通过高效液相色谱和放免法测定大鼠肾素—血管紧张素—醛固酮系统和心房利钠肽(ANP)血浆浓度的变化。③SGL-1体外实验。采用噻唑蓝、Hoechst33258染色法观察SGL-1的抗细胞凋亡作用,检测乳酸脱氢酶以量化SGL-1的抗细胞损伤作用,检测活性氧、丙二醛、超氧化物歧化酶、谷胱甘肽过氧化物酶活性评价SGL-1的抗氧化作用,并通过噻唑蓝染色法考察了SGL-1对阿霉素抗肿瘤活性的影响。
结果①SGL-3可以显著抑制Angiotensin-Ⅱ刺激引起的心肌细胞肥大,通过H~3掺入实验可观察到蛋白合成量显著下降(减少74%±26%),通过鬼笔环肽染色可观察到细胞表面积显著减少(下降104%±31%)。②体内实验结果显示,SGL-3能够改善心脏的收缩功能(AAC组EF值为51.8%±8.42%,假手术组EF值为75.6%±7.65%,SGL-3治疗组EF值为69.3%±7.73%,卡托普利与倍他乐克合用组的EF值为56.3%±8.41%)。病理学检查则发现SGL-3能够明显抑制AAC引起的心肌细胞肥大、心肌纤维化。通过高效液相色谱和放免法测定,发现肾素—血管紧张素—醛固酮系统和ANP血浆浓度均有一定程度的改善(与模型组相比,p＜0.05)。
③SGL-1可以显著减轻阿霉素引起的细胞凋亡(82.8%vs.48.8%)和细胞损伤(1.83倍vs.1.23倍),清除活性氧,降低丙二醛浓度(2.5倍vs.1.46倍),使超氧化物歧化酶(58.9%vs.89.3%)、谷胱甘肽过氧化物酶(46.1%vs.87.3%)活性恢复至接近正常水平,并且不影响阿霉素的抗肿瘤活性(30.9%vs.29.5%)。
结论①SGL-3可以减轻心肌细胞肥大,抑制心肌肥厚向心力衰竭发展的进程。其机制可能与SGL-3改善心功能,抑制后负荷增高引起的肾素—血管紧张素—醛固酮系统激活有关。②SGL-1可以显著减轻阿霉素引起的心肌细胞凋亡和损伤,其机制与SGL-1清除活性氧,改善细胞内氧化应激状态有关。
Background Pheochromocytoma is a rare tumor of adrenal medulla.If the tumor is not diagnosed and treated in time,it could lead to various cardiovascular or cerebrovascular diseases and even death.The imaging or biochemical tests now used for detecting pheochromocytoma have been proved to have some shortages,such as low sensitivity or specificity.Recently both metanephrine and normetanephrine,two O-methylated metabolites of catecholamine,were recognized internationally as the preferred monitoring indicators for pheochromocytoma.The objectives of this study are to establish the method of measuring metanephrine and normetanephrine in 24h urine using high performance liquid chromatography,to investigate its application and reliability,and to set up the diagnostic criteria and range of normal values.Moreover,the superiority of metanephrine and normetanephrine measurement in the diagnosis of the pheochromocytoma could be validated by comparing catecholamine levels in plasma and urine.
Methods In the study,solid-phase extraction cartridge is used for the extraction of metanephrine and normetanephrine from the samples,and high performance liquid chromatography is used for their measurement.The variations of equipment,intra-assay variations,inter-assay variations and recoveries of metanephrine and normetanephrine were detected to examine the stability of the method.The measurement of metanephrines in 24h urine samples of 324 hypertensive non-pheochromocytoma patients(controls) and 7 verified pheochromocytoma patients(cases) were carried out by the method.The diagnostic criteria of metanephrine and normetanephrine were established by using receiver operating characteristic curves,and their range of normal values was set up by percentile rank method.The concentration of catecholamine in plasma and 24h urine of all patients and most controls were measured.
Results①Peak value of both metanephrine and normetanephrine were detected within 10 minutes.②The variations of equipment,intra-assay variations,inter-assay variations and recoveries of metanephrine were 2.3%,5.5%,5.1%and 93.4% respectively,while the corresponding values of normetanephrine were 1.9%,4.8%,4.7% and 87.9%.③The average values of metanephrine and normetanephrine in controls were 152±114μg/24h and 294±267μg/24h,while the corresponding values for cases were 1426±1956μg/24h and 4376±2591μg/24h.④The diagnostic criteria and 99% upper of normal values of metanephrine were 415μg/24h and 419μg/24h,while the relevant values for normetanephrine were 1464μg/24h and 1184μg/24h.⑤The sensitivity and specificity of metanephrine were 71.4%and 98.8%,and the corresponding figures for normetanephrine were 100%and 100%.The diagnostic sensitivity and specificity of plasma catecholamines were 71.4%and 79.0%,and the corresponding figures for 24h urine catecholamines were 100%and 82.4%.
Conclusion A quick,reliable and accurate method of quantifying metanephrine and normetanephrine in 24h urine was established by using high performance liquid chromatographic assay,and the diagnostic criteria and range of normal values of these two indexes were set up first time in China.In comparison with the plasma and 24h urine catecholamines,the measurement of metanephrine and normetanephrene is now the best biochemical assay for detecting pheochromocytomas.
Background
Although the treatment of congestive heart failure(CHF) has improved a lot during last decades of years,the morbidity and mortality of CHF are still at high levels.Therefore,it is still an important and necessary work to develop new anti-heart failure drugs.SGL-3 is a traditional Chinese medicine,and has been proved to be very effective in the treatment of CHF.One of the objectives of this study was to demonstrate the protective effects of SGL-3 through in vitro and in vivo experiments,and to find out its pharmacological mechanism.SGL-1 is a flavone compound which has been proved to be a powerful antioxidant.Since the excessive reactive oxygen species(ROS) plays an important role in the process of doxorubicin-induced cardiotoxicity,we tried to demonstrate the protective effects of SGL-1 against doxorubicin-induced apoptosis and injury in H9c2 cells.
Methods
①SGL-3 in vitro study.In cultured rat neonatal cardiac myocytes,the inhibition of angiotensin-Ⅱ-induced(1μmol/L)cardiac myocyte hypertrophy by SGL-3(10μg/mL) was observed using[~3H]leucine incorporation and phalloidine assay.
②SGL-3 in vivo study.In vivo,twenty-weeks-old male Wistar rats were subjected to suprarenal abdominal aorta constriction(AAC) operation(n=48) or sham operation (n=12).Twenty weeks after surgery,heart failure was detected in AAC rats by using echocardiography,then the AAC rats were treated with either SGL-3(150 mg·kg~(-1)·d~(-1), 500 mg·kg~(-1)·d~(-1) and 1500 mg·kg~(-1)·d~(-1),PO,n=12 in each group) or Captopril(270 mg·kg~(-1)·d~(-1),PO) plus Metoprolol(1,800 mg·kg~(-1)·d~(-1),PO)(n=12) for 18 weeks respectively.Cardiac hemodynamic and morphological parameters were obtained by using multi-functional physiology recorder and echocardiography.The pathologic changes were observed using hematoxylin and eosin staining,masson staining and sirius red staining.Moreover,the levels of plasma ANP and other indexes of renin-angiotensin-aldosterone system(RAAS) were also measured.
③SGL-1 in vitro study.The 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide(MTT) staining,Hoechst33258 staining and lactate dehydrogenase(LDH) measurement were used to investigate the anti-apoptosis effect of SGL-1.The reactive oxygen species were observed using 2,7-dichlorofluorescein diacetate(DCFH-DA) probe,while the activities of malondialdehyde(MDA),superoxide dismutase(SOD) and glutathione peroxidase(GPx) were measured to investigate the antioxidative activity of SGL-1.
Results
①In cultured rat neonatal cardiac myocytes,SGL-3 significantly inhibited cardiac myocyte hypertrophy which was induced by angiotensin-Ⅱ,reduced[~3H]leucine incorporation by 74%±26%and cell surface area by 104%±31%.
②The in vivo results revealed that SGL-3 could improve cardiac systolic function more effectively(EF:51.8%±8.42%for AAC group,75.6%±7.65%for sham operation group, 69.3%±7.73%for SGL-3 treated group) than Captopril plus Metoprolol(EF: 56.3%±8.41%).Histological examination of cardiac structure showed that the extent of cardiac myocyte hypertrophy was restrained,and in compare with vehicle,myocardial fibrosis,circulating renin-aldosterone system and ANP secreting were remarkedly inhibited in AAC rats treated with SGL-3(p＜0.05).
③In H9c2 cells,SGL-1 significantly relieved doxorubicin-induced apoptosis(82.8%vs. 48.8%) and cell injury(1.83 times compared with control vs.1.23 times),reduced the production of ROS and MDA(2.5 times vs.1.46 times),and raised the activities of SOD (58.9%vs.89.3%) and GPx(46.1%vs.87.3%).Moreover,we found that SGL-1 did not influence the anticancer activity of doxorubicin(30.9%vs.29.5%).
Conclusions
①SGL-3 attenuated the cardiac myocyte hypertrophy both in vitro and in vivo and inhibited the process from hypertrophy to heart failure.The major mechanisms might be the improvement of cardiac functions and the inhibition of RAAS.②SGL-1 significantly reduced the apoptosis and injury induced by doxorubicin.These effects might be related to the scavenging of ROS and the improvement of oxidative stress in cardiac myocytes.
方法首先通过加热使结合型变肾上腺素类物质转化为游离型变肾上腺素类物质,然后使用固相萃取柱进行提取,蒸干重溶后采用高效液相色谱-电化学法进行检测。通过测定仪器变异、批内变异、批间变异和回收率来考察方法的稳定性。然后用此方法对324例高血压非嗜铬细胞瘤患者(对照组)和7例嗜铬细胞瘤患者(病例组)进行了变肾上腺素类物质的检查,运用受试者工作曲线确定诊断标准,用百分位法确定正常值范围。同时对部分病例的血浆儿茶酚胺或24h尿儿茶酚胺进行了检测。
结果①变肾上腺素、变去甲肾上腺素的出峰时间均不超过10分钟;②变肾上腺素的仪器变异、组内变异、批间变异和回收率分别为2.3%、5.5%、5.1%、93.4%;变去甲肾上腺素的仪器变异、组内变异、批间变异和回收率分别为1.9%、4.8%、4.7%、87.9%;③对照组的变肾上腺素检测值为152±114μg/24h,变去甲肾上腺素检测值为294±267μg/24h,病例组的变肾上腺素检测值为1426±1956μg/24h,变去甲肾上腺素检测值为4376±2591μg/24h;④变肾上腺素的诊断标准为415μg/24h,99%正常值范围上限为419μg/24h,变去甲肾上腺素的诊断标准为1464μ∥24h,99%正常值范围上限为1184μg/24h;⑤变肾上腺素诊断的灵敏度为71.4%,特异度为98.8%,变去甲肾上腺素诊断的灵敏度为100%,特异度为100%,血浆去甲肾上腺素诊断的灵敏度为71.4%,特异度为79.0%,24小时尿去甲肾上腺素诊断的灵敏度为100%,特异度为82.4%。
结论本研究建立了快速、稳定、准确的24小时尿变肾上腺素类物质的检测方法,并在国内首次确立了其诊断标准和正常值范围;相比血浆、尿儿茶酚胺等检测指标,变肾上腺素类物质是目前临床检验嗜铬细胞瘤的最佳指标。
背景在过去的几十年中,尽管人们对充血性心力衰竭的认识逐渐加深,治疗手段和治疗效果也有了明显改善,但心衰患者的发病率和死亡率依然居高不下,开发新的心衰治疗药物仍具有重要而迫切的临床意义。SGL-3是一个传统中药组方,经长期临床应用证明对心力衰竭具有显著的改善作用。本研究的目的之一即通过体内、体外实验验证SGL-3对心力衰竭的治疗效果,并初步探讨其作用机制。SGL-1是一个黄酮类化合物单体,经前期实验证明具有强抗氧化性,而在心力衰竭尤其是过量应用抗癌药物阿霉素导致的心脏毒性中,活性氧的产生是最重要的作用机理,因此,本研究的另一目的是通过体外实验验证SGL-1对阿霉素所致心脏毒性的改善作用,为进一步研究SGL-1在治疗心力衰竭中的应用和机理打下基础。
方法①SGL-3体外实验。采用Angiotensin-Ⅱ(1μmol/L)刺激原代培养的乳鼠心肌细胞引起心肌细胞的肥大,通过H~3掺入实验和鬼笔环肽染色观察SGL-3(10μg/mL)对心肌细胞肥大的抑制作用。②SGL-3体内试验。采用20周龄雄性Wistar大鼠,对大鼠进行腹主动脉缩窄手术(AAC)或假手术,20周后,通过超声心动图检测确定术后大鼠出现的心脏功能异常。之后将动物分组,灌胃给药,SGL-3的给药浓度为:150 mg·kg~(-1)·d~(-1)、500 mg·kg~(-1)·d~(-1)和1,500 mg·kg~(-1)·d~(-1),同时设置对照组,即卡托普利(270 mg·kg~(-1)·d~(-1))与倍他乐克(1,800 mg·kg~(-1)·d~(-1))合用组,给药18周。然后使用多导生理仪和超声心动图检测不同组大鼠的射血分数(EF)等心脏血流动力学和形态学参数,采用苏木素—伊红染色、masson染色及天狼猩红染色进行了病理学检查,并通过高效液相色谱和放免法测定大鼠肾素—血管紧张素—醛固酮系统和心房利钠肽(ANP)血浆浓度的变化。③SGL-1体外实验。采用噻唑蓝、Hoechst33258染色法观察SGL-1的抗细胞凋亡作用,检测乳酸脱氢酶以量化SGL-1的抗细胞损伤作用,检测活性氧、丙二醛、超氧化物歧化酶、谷胱甘肽过氧化物酶活性评价SGL-1的抗氧化作用,并通过噻唑蓝染色法考察了SGL-1对阿霉素抗肿瘤活性的影响。
结果①SGL-3可以显著抑制Angiotensin-Ⅱ刺激引起的心肌细胞肥大,通过H~3掺入实验可观察到蛋白合成量显著下降(减少74%±26%),通过鬼笔环肽染色可观察到细胞表面积显著减少(下降104%±31%)。②体内实验结果显示,SGL-3能够改善心脏的收缩功能(AAC组EF值为51.8%±8.42%,假手术组EF值为75.6%±7.65%,SGL-3治疗组EF值为69.3%±7.73%,卡托普利与倍他乐克合用组的EF值为56.3%±8.41%)。病理学检查则发现SGL-3能够明显抑制AAC引起的心肌细胞肥大、心肌纤维化。通过高效液相色谱和放免法测定,发现肾素—血管紧张素—醛固酮系统和ANP血浆浓度均有一定程度的改善(与模型组相比,p＜0.05)。
③SGL-1可以显著减轻阿霉素引起的细胞凋亡(82.8%vs.48.8%)和细胞损伤(1.83倍vs.1.23倍),清除活性氧,降低丙二醛浓度(2.5倍vs.1.46倍),使超氧化物歧化酶(58.9%vs.89.3%)、谷胱甘肽过氧化物酶(46.1%vs.87.3%)活性恢复至接近正常水平,并且不影响阿霉素的抗肿瘤活性(30.9%vs.29.5%)。
结论①SGL-3可以减轻心肌细胞肥大,抑制心肌肥厚向心力衰竭发展的进程。其机制可能与SGL-3改善心功能,抑制后负荷增高引起的肾素—血管紧张素—醛固酮系统激活有关。②SGL-1可以显著减轻阿霉素引起的心肌细胞凋亡和损伤,其机制与SGL-1清除活性氧,改善细胞内氧化应激状态有关。
Background Pheochromocytoma is a rare tumor of adrenal medulla.If the tumor is not diagnosed and treated in time,it could lead to various cardiovascular or cerebrovascular diseases and even death.The imaging or biochemical tests now used for detecting pheochromocytoma have been proved to have some shortages,such as low sensitivity or specificity.Recently both metanephrine and normetanephrine,two O-methylated metabolites of catecholamine,were recognized internationally as the preferred monitoring indicators for pheochromocytoma.The objectives of this study are to establish the method of measuring metanephrine and normetanephrine in 24h urine using high performance liquid chromatography,to investigate its application and reliability,and to set up the diagnostic criteria and range of normal values.Moreover,the superiority of metanephrine and normetanephrine measurement in the diagnosis of the pheochromocytoma could be validated by comparing catecholamine levels in plasma and urine.
Methods In the study,solid-phase extraction cartridge is used for the extraction of metanephrine and normetanephrine from the samples,and high performance liquid chromatography is used for their measurement.The variations of equipment,intra-assay variations,inter-assay variations and recoveries of metanephrine and normetanephrine were detected to examine the stability of the method.The measurement of metanephrines in 24h urine samples of 324 hypertensive non-pheochromocytoma patients(controls) and 7 verified pheochromocytoma patients(cases) were carried out by the method.The diagnostic criteria of metanephrine and normetanephrine were established by using receiver operating characteristic curves,and their range of normal values was set up by percentile rank method.The concentration of catecholamine in plasma and 24h urine of all patients and most controls were measured.
Results①Peak value of both metanephrine and normetanephrine were detected within 10 minutes.②The variations of equipment,intra-assay variations,inter-assay variations and recoveries of metanephrine were 2.3%,5.5%,5.1%and 93.4% respectively,while the corresponding values of normetanephrine were 1.9%,4.8%,4.7% and 87.9%.③The average values of metanephrine and normetanephrine in controls were 152±114μg/24h and 294±267μg/24h,while the corresponding values for cases were 1426±1956μg/24h and 4376±2591μg/24h.④The diagnostic criteria and 99% upper of normal values of metanephrine were 415μg/24h and 419μg/24h,while the relevant values for normetanephrine were 1464μg/24h and 1184μg/24h.⑤The sensitivity and specificity of metanephrine were 71.4%and 98.8%,and the corresponding figures for normetanephrine were 100%and 100%.The diagnostic sensitivity and specificity of plasma catecholamines were 71.4%and 79.0%,and the corresponding figures for 24h urine catecholamines were 100%and 82.4%.
Conclusion A quick,reliable and accurate method of quantifying metanephrine and normetanephrine in 24h urine was established by using high performance liquid chromatographic assay,and the diagnostic criteria and range of normal values of these two indexes were set up first time in China.In comparison with the plasma and 24h urine catecholamines,the measurement of metanephrine and normetanephrene is now the best biochemical assay for detecting pheochromocytomas.
Background
Although the treatment of congestive heart failure(CHF) has improved a lot during last decades of years,the morbidity and mortality of CHF are still at high levels.Therefore,it is still an important and necessary work to develop new anti-heart failure drugs.SGL-3 is a traditional Chinese medicine,and has been proved to be very effective in the treatment of CHF.One of the objectives of this study was to demonstrate the protective effects of SGL-3 through in vitro and in vivo experiments,and to find out its pharmacological mechanism.SGL-1 is a flavone compound which has been proved to be a powerful antioxidant.Since the excessive reactive oxygen species(ROS) plays an important role in the process of doxorubicin-induced cardiotoxicity,we tried to demonstrate the protective effects of SGL-1 against doxorubicin-induced apoptosis and injury in H9c2 cells.
Methods
①SGL-3 in vitro study.In cultured rat neonatal cardiac myocytes,the inhibition of angiotensin-Ⅱ-induced(1μmol/L)cardiac myocyte hypertrophy by SGL-3(10μg/mL) was observed using[~3H]leucine incorporation and phalloidine assay.
②SGL-3 in vivo study.In vivo,twenty-weeks-old male Wistar rats were subjected to suprarenal abdominal aorta constriction(AAC) operation(n=48) or sham operation (n=12).Twenty weeks after surgery,heart failure was detected in AAC rats by using echocardiography,then the AAC rats were treated with either SGL-3(150 mg·kg~(-1)·d~(-1), 500 mg·kg~(-1)·d~(-1) and 1500 mg·kg~(-1)·d~(-1),PO,n=12 in each group) or Captopril(270 mg·kg~(-1)·d~(-1),PO) plus Metoprolol(1,800 mg·kg~(-1)·d~(-1),PO)(n=12) for 18 weeks respectively.Cardiac hemodynamic and morphological parameters were obtained by using multi-functional physiology recorder and echocardiography.The pathologic changes were observed using hematoxylin and eosin staining,masson staining and sirius red staining.Moreover,the levels of plasma ANP and other indexes of renin-angiotensin-aldosterone system(RAAS) were also measured.
③SGL-1 in vitro study.The 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide(MTT) staining,Hoechst33258 staining and lactate dehydrogenase(LDH) measurement were used to investigate the anti-apoptosis effect of SGL-1.The reactive oxygen species were observed using 2,7-dichlorofluorescein diacetate(DCFH-DA) probe,while the activities of malondialdehyde(MDA),superoxide dismutase(SOD) and glutathione peroxidase(GPx) were measured to investigate the antioxidative activity of SGL-1.
Results
①In cultured rat neonatal cardiac myocytes,SGL-3 significantly inhibited cardiac myocyte hypertrophy which was induced by angiotensin-Ⅱ,reduced[~3H]leucine incorporation by 74%±26%and cell surface area by 104%±31%.
②The in vivo results revealed that SGL-3 could improve cardiac systolic function more effectively(EF:51.8%±8.42%for AAC group,75.6%±7.65%for sham operation group, 69.3%±7.73%for SGL-3 treated group) than Captopril plus Metoprolol(EF: 56.3%±8.41%).Histological examination of cardiac structure showed that the extent of cardiac myocyte hypertrophy was restrained,and in compare with vehicle,myocardial fibrosis,circulating renin-aldosterone system and ANP secreting were remarkedly inhibited in AAC rats treated with SGL-3(p＜0.05).
③In H9c2 cells,SGL-1 significantly relieved doxorubicin-induced apoptosis(82.8%vs. 48.8%) and cell injury(1.83 times compared with control vs.1.23 times),reduced the production of ROS and MDA(2.5 times vs.1.46 times),and raised the activities of SOD (58.9%vs.89.3%) and GPx(46.1%vs.87.3%).Moreover,we found that SGL-1 did not influence the anticancer activity of doxorubicin(30.9%vs.29.5%).
Conclusions
①SGL-3 attenuated the cardiac myocyte hypertrophy both in vitro and in vivo and inhibited the process from hypertrophy to heart failure.The major mechanisms might be the improvement of cardiac functions and the inhibition of RAAS.②SGL-1 significantly reduced the apoptosis and injury induced by doxorubicin.These effects might be related to the scavenging of ROS and the improvement of oxidative stress in cardiac myocytes.
引文
[1]Moser M,Setaro JF.Resistant or difficult-to-control hypertension.N Engl J Med,2006,355:385-392.
[2]McNeil AR,Blok BH,Koelmeyer TD,et al.Phaeochromocytomas discovered during coronial autopsies in Sydney,Melbourne and Auckland.Aust NZ J Med,2000,30:648-652.
[3]John H,Ziegler WH,Hauri D,et al.Pheochromocytomas:can malignant potential be predicted? Urology,1999,53:679-683.
[4]Mundschenk J,Lehnert H.Malignant pheochromocytoma.Exp Clin Endocrinol Diabetes.1998,106:373-376.
[5]Lin DD,Loughlin KR.Diagnosis and management of surgical adrenal diseases.Urology,2005,66:476-483.
[6]Amar L,Servais A,Gimenez-Roqueplo AP,et al.Year of diagnosis,features at presentation,and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma.J Clin Endocrinol Metab,2005,90:2110-2116.
[7]Grumbach MM,Biller BM,Braunstein GD,et al.Management of the clinically inapparent adrenal mass (“incidentaloma” ).Ann Intern Med,2003,138:424-429.
[8]Mannelli M,lanni L,Cilotti A,et al.Pheochromocytoma in Italy:A multicentric retrospective study.Eur J Endocrinol,1999,141:619-624.
[9]Mantero F,Terzolo M,Arnaldi G,et al.A survey on adrenal incidentaloma in Italy.Study Group on Adrenal Tumors of the Italian Society of Endocrinology.J Clin Endocrinol Metab,2000,85:637-644.
[10]Kasperlik-Zaluska AA,Roslonowska E,Slowinska-Srzednicka J,et al.1111 Patients with adrenal incidentalomas observed at a single endocrinological center:Incidence of chromaffin tumors.Ann NY Acad Sci,2006,1073:38-46.
[11]Whalen RK,AlthausenAF,Daniels GH.Extra-adrenal pheochromocytoma.J Urol,1992,147:1-10.
[12]Pacak K,LinehanWM,EisenhoferG,et al.Recent advances in genetics,diagnosis,localization,and treatment of pheochromocytoma.Ann Intern Med,2001,134:315-329.
[13]郑德裕,佟万仁,惠汝太。继发性高血压诊断治疗学。人民军医出版社,北京,2005年9月第l版。
[14]Lenders J H,Pacak K,Halther MM,et al.Biochemical diagnosis of pheochromocytoma:which test is best? JAMA,2002,287:1427-1434.
[15]Eisenhofer G.Free or total metanephrines for diagnosis of pheochromocytoma:what is the difference? Clin Chem,2001,47:988-998.
[16]Roden M.How to detect pheochromocytomas?—the diagnostic relevance of plasma free metanephrines.Hien Klin Hochenschr,2002,114:246-251.
[17]Eisenbofer G,Keiser HR,Friberget P,et al.Plasma metanephrines are markers of pheochromocytoma produced by catechol-O-methyltransferase within tumors? J Clin Endocrinol Metab,1998,83:2175-2185.
[18]Raber W,Raffesberg W,Bischof M,et al.Diagnostic efficacy of unconjugated plasma metanephrines for the detection of pheochromocytoma.Arch Intern Med,2000,160:2957-2963.
[19]Pacak K,Goldstein D,Doppman J,et al.A "Pheo" lurks:novel approaches for locating occult pheochromocytoma.J Clin Endocrinal Metab,2001,86:3641-3646.
[20]Hoizey G,Lucas CC,Frances C,et al.Study of diurnal fluctuations of plasma methoxyamines in healthy volunteers.Clin Endocrinal (Oxf),2002,56:119-122.
[21]Molnar I,Horvath C.Reverse-phase chromatography of polar biological substances:separation of catechol compounds by high-performance liquid chromatography.Clin Chem,1976,22(9):1497-1502.
[22]Shoup RE,Kissinger PT.Determination of urinary normetanephrine,metanephrine,and 3-methoxytyramine by liquid chromatography,with amperometric detection.C]in Chem,1977,23(7):1268-1274.
[23]Peterson ZD,Collins DC,Bowerbank CR,et al.Determination of catecholamines and metanephrines in urine by capillary electrophoresis-electrospray ionization-time-of-flight mass spectrometry.J Chromatogr B Analyt Technol Biomed Life Sci,2002,776(2):221-229.
[24]Claver Canfell,Steven R.Quantitation of Urinary Normetanephrine and Metanephrine by Reversed-Phase Extraction and Mass-Fragment ographic Analysis.Clin Chem,1982,28(1):25-28.
[25]Wolthers BG,Kema IP,Volmer M,et al.Evaluation of urinary metanephrine and normetanephrine enzyme immunoassay (ELISA)kits by comparison with isotope dilution mass spectrometry.Clin Chem,1997,43(1):114-120.
[26]Karel Pacak,Graeme Eisenhofer,Hakan Ahlman,et al.Pheochromocytoma:recommendations for clinical practice from the First International Symposium.Nature Clinical Practice Endocrinology & Metabolism,2007,3(2):92-102.
[27]Nancy C.Parker,Cyndy B.Levtzow,Patricia W.Wright,et al.Uniform Chromatographic Conditions for Quantifying Urinary Catecholamines,Metanephrines,VaniHylmandelic Acid,5-Hydroxyindoleacetic Acid,by Liquid Chromatography,with Electrochemical Detection.Clin Chem,1986,32(8):1473-1476.
[28]Paul H.Gamache,Manning L.Kingery and Ian N.Acworth.Urinary Metanephrine and Normetanephrine Determined without Extraction by Using Liquid Chromatography and Coulometric Array Detection.Clin Chem,1993,39(9):1825-1830.
[29]Paul J.Orsulak,Patricia Kizuka,Edwin Grab,et al.Determination of Urinary Normetanephrine and Metanephrine by Radial-Compression Liquid Chromatography and Electrochemical Detection.Clin Chem,1983,29(2):305-309.
[30]James G.Flood and Robert B.McComb.Urinary Metanephrines as Measured by Liquid Chromatography with an 0n-Line Post-Column Reaction Detector.Clin Chem,1981,27(7):1268-1271.
[31]Willemsen JJ,Sweep CG,Lenders JW,et al.Stability of Plasma Free Metanephrines during Collection and Storage as Assessed by an Optimized HPLC Method with Electrochemical Detection,Clin Chem,2003,49(11):1951-1953.
[32]Willemsen JJ,Ross HA,Lenders WM,et al.Stability of urinary fractionated metanephrines and catecholamines during collection,shipment and storage of samples.Clin Chem,2007,53:268-272.
[1]Moser M,Setaro JF.Resistant or difficult-to-control hypertension.N Engl J Med,2006,355:385-392.
[2]McNeil AR,Blok BH,Koelmeyer TD,et al.Phaeochromocytomas discovered during coronial autopsies in Sydney,Melbourne and Auckland.Aust NZ J Med,2000,30:648-652.
[3]John H,Ziegler WH,Hauri D,et al.Pheochromocytomas:can malignant potential be predicted? Urology,1999,53:679-683.
[4]Mundschenk J,Lehnert H.Malignant pheochromocytoma.Exp Clin Endocrinol Diabetes.1998,106:373-376.
[5]Lin DD,Loughlin KR.Diagnosis and management of surgical adrenal diseases.Urology,2005,66:476-483.
[6]Amar L,Servais A,Gimenez-Roqueplo AP,et al.Year of diagnosis,features at presentation,and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma.J Clin Endocrinol Metab,2005,90:2110-16.
[7]Grumbach MM,Biller BM,Braunstein GD,et al.Management of the clinically inapparent adrenal mass (“incidentaloma”).Ann Intern Med,2003,138:424-429.
[8]Mannelli M,Ianni L,Cilotti A,et al.Pheochromocytoma in Italy:A multicentric retrospective study.Eur J Endocrinol,1999,141:619-624.
[9]Mantero F,Terzolo M,Arnaldi G,et al.A survey on adrenal incidentaloma in Italy.Study Group on Adrenal Tumors of the Italian Society of Endocrinology.J Clin Endocrinol Metab,2000,85:637-644.
[10]Kasperlik-Zaluska AA,Roslonowska E,Slowinska-Srzednicka J,et al.1111 Patients with adrenal incidentalomas observed at a single endocrinological center:Incidence of chromaffin tumors.Ann NY Acad Sci,2006,1073:38-46.
[11]Whaien RK,Althausen AF,Daniels GH.Extra-adrenal pheochromocytoma.J Urol,1992,147:1-10.
[12]Pacak K,Linehan WM,Eisenhofer G,et al.Recent advances in genetics,diagnosis,localization,and treatment of pheochromocytoma.Ann Intern Med,2001,134:315-29.
[13]Lenders JW,Eisenhofer G,Mannelli M,et al.Phaeochromocytoma.Lancet,2005,366:665-675.
[14]Eisenhofer G,Kopin IJ,Goldstein DS.Catecholamine metabolism:A contemporary view with implications for physiology and medicine.Pharmacol Rev,2004b,56:331-349.
[15]Willemsen JJ,Sweep CG,Lenders JW,et al.Stability of Plasma Free Metanephrines during Collection and Storage as Assessed by an Optimized HPLC Method with Electrochemical Detection,Clinical Chemistry,2003,49(11):1951-1953.
[16]Willemsen JJ,Ross HA,Lenders WM,et al.Stability of urinary fractionated metanephrines and catecholamines during collection,shipment and storage of samples.Clin Chem,2007,53:268-272.
[17]Lenders JW,Pacak K,Walther MM,et al.Biochemical diagnosis of pheochromocytoma:Which test is best? JAMA,2002,287:1427-1434.
[18]Karel Pacak,Graeme Eisenhofer,Hakan Ahlman,et al.Pheochromocytoma:recommendations for clinical practice from the First International Symposium.Nature Clinical Practice Endocrinology & Metabolism,2007,3(2):92-102.
[19]Richard MB,Denise ML,Stephen B.Plasma catecholamine and nephrine responses to brief intermittent maximal intensity exercise.Amino Acids,spriger.2008,36(2):209-217.
[20]Mazza A,Zamboni S,Armigliato M,et al.Endocrine arterial hypertension:diagnostic approach in clinical practice.Minerva Endocrinol,2008,33:127-146.
[21]Eisenhofer G,Goldstein DS,Walther MM,et al.Biochemical diagnosis of pheochromocytoma:How to distinguish true-from false-positive test results.J Clin Endocrinol Metab,2003,88:2656-2666.
[22]Bravo EL,Tarazi RC,Fouad FM,et al.Clonidine-suppression test:A useful aid in the diagnosis of pheochromocytoma.N Engl J Med,1981,305:623-626.
[23]Zelinka T,Eisenhofer G,Pacak K.Pheochromocytoma as a catecholamine producing tumor:Implications for clinical practice.Stress,2007,10(2):195-203.
[24]Robert TP,Stephen B.Biochemical detection of phaeochromocytoma:why are we continuing to ignore the evidence? Ann Clin Biochem,2008,45:6-10.
[25]JohnH,Ziegler WH,HauriD,et al.Pheochromocytomas:Can malignant potential be predicted? Urology,1999,53:679-683.
[1]Adams JW,Sakata Y,Davis MG,et al.Enhanced Gaq signaling:a common pathway mediates cardiac hypertrophy and apoptotic heart failure.Proc Natl Acad Sci USA,1998,95(17):10140-10145.
[2]Akhter SA,Milano CA,Shotwell KF,et al.Transgenic mice with cardiac overexpression of IB-adrenergic receptors,J Biol Chem,1997,272:21253-21259.
[3]Akhter SA,Luttrell LM,Rockman HA,et al.Targeting the receptor-Gq interface to inhibit in vivo pressure overload myocardial hypertrophy.Science,1998,280:574-577.
[4]Akhter SA,Eckhart AD.In vivo inhibition of elevated myocardial adrenergic receptor kinase activity in hybrid transgenic mice restores normal adrenergic signaling and function.Circulation,1999,100:648-653.
[5]Anker SD,Chau TP,Ponikowski P,et al.Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia.Circulation,1997,96:526-534.
[6]Asai K,Yang GP,Geng YJ,et al.Adrenergic receptor blockade arrests myocyte damage and preserves cardiac function in the transgenic Gs mouse.J Clin Invest,1999,104:551-558.
[7]Baker A J,Redfern CH,Harwood MD,et al.Abnormal contraction caused by expression of Gi coupled receptor in transgenic model of dilated cardiomyopathy.Am J Physiol,2001,280:H1653-H1659.
[8]Bristow MR,Ginsburg R,Minobe W,et al.Decreased catecholamine sensitivity and adrenergic receptor density in failing human hearts.N Engl J Med,1982,307:205-211.
[9]Bristow MR,Herschberger RE.Adrenergic receptor mediated adenylyl cyclase stimulation in non-failing and failing human ventricular myocardium.Mol Pharmacol,1989,35:395-399.
[10]Bristow MR,Minobe W,Raynolds MV,et al.Reduced receptor messenger RNA abundance in the failing human heart.J Clin Invest,1993,92:2737-2745.
[11]Chein KR.Stress pathways and heart failure.Cell,1999,98:555-558.
[12]Choi D-J,Koch WJ,Hunter JJ,et al.Mechanism for adrenergic receptor desensitization in cardiac hypertrophy is increased adrenergic receptor kinase.J Biol Chem,1997,272:17223-17229.
[13]Chu G,Haghighi K,Kranias EG.From mouse to man:understanding heart failure through genetically altered mouse models.J Card Failure,2002,8:S432-S449
[14]Clapham DE,Neer EJ.G protein beta gamma subunits.Annu Rev Pharmacol Toxicol.1997,37:167-203.
[15]Cohn JN,Levine TB,Olivari MT,et al.Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure.N Engl J Med,1984,311:819-823.
[16]Dorn GW Ⅱ,Tepe NM,Lorenz JN,et al.Low and high adrenergic receptors differentially affect cardiac hypertrophy and function in Gaq overexpressing mice.Proc Natl Acad Sci USA,1999,96:6400-6405.
[17]Du X-J,Autelitano DJ,Dilley RJ,et al.02 adrenergic receptor overexpression exacerbates development of heart failure after aortic Stenosis.Circulation,2000,101:71-77.
[18]Woodruff JF.Viral myocarditis:a review.Am J Pathol 1980,101:427-479.
[19]Drory Y,Turetz Y,Hiss Y,et al.Sudden unexpected death in persons less than 40 years of age.Am J Cardiol 1991,68:1388-1392.
[20]Kawai C.From myocarditis to cardiomyopathy:mechanisms of inflammation and cell death.Circulation 1999,99:1091-1100.
[21]Fuster V,Gersh BJ,Giuliani ER,Tajik AJ,Brandenburg RO,Frye RL.The natural history of idiopathic dilated cardiomyopathy.Am J Cardiol 1981,47:525-531.
[22]Feldman AM,McNamara D.Myocarditis.N Engl J Med 2000,343:1388-1398.
[23]Bean B.Antiviral therapy:current concept and practices.Clin.Microbiol 1992,5:146-182.
[24]Zoulim F,Haem J,Ahmed SS,et al.Ribavirin monotherapy in patients with chronic hepatitis C:a retro-spective study of 95 patients.J Viral Hepat 1998,5:193-198.
[25]Weislow OS,Kiser R,Fine DL,Bader J,Shoemaker RH,Boyd MR.New soluble-formazan assay for HIV-1 cytopathic effects:application to highflux screening of synthetic and natural products for AIDS-antiviral activity.J Natl Cancer Inst 1989,81:577-586.
[26]Pauwels R,Balzarini J,Baba M,et al.Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds.J Virol methods 1988,20:309-321.
[27]Logu AD,Loy G,Pellerano ML,Bonsignore L,Schivo ML.Inactivation of HSV-1 and HSV-2 and prevention of cell-to-cell virus spread by Santolina insularis essential oil.Antiviral Res 2000,48:177-185.
[28]Scudiero DA,Shoemaker RH,Paull KD,et al.Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines.Cancer Res 1998,48:4827-4833.
[29]Boulware SL,Bronstein JC,Nordby EC,Weber PC.Identification and characterization of benzothiophene inhibitor of herpes simplex virus type 1 replication which acts at the immediate early stage of infection.Antiviral Res 2001,51:111-125.
[30]Bergelson JM,Modlin JF,Wieland-Alter W,Cunningham JA,Crowell RL,Finberg RW.Clinical coxsackievirus B isolates differ from laboratory strains in their interaction with two cell surface receptors.J Infect Dis 1997,175:697-700.
[31]Muckelbauer JK,Kremer M,Minor I,et al.The structure of coxsackievirus B3 at 3.5 Angstrom resolution.Structure 1995,3:653-667.
[32]He Y,Chipman PR,Howitt J,et al.Interaction of coxsackievirus B3 with the full length coxsackievirus-adenovirus receptor.Nat Struct Biol 2001,8:874-878.
[33]Rossmann MG.The canyon hypothesis.Viral Immunol 1989,2:143-161.
[34]Bergelson JM,Cunningham JA,Droguett G,et al.Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5.Science 1997,275:1320-1323.
[35]Shafren DR,Williams DT,Barry RD.A decay-accelerating factor-binding strain of coxsackievirus B3 requires the coxsackievirus-adenovirus receptor protein to mediate lytic infection of rhabdomyosarcoma cells.J Virol 1997,71:9844-9848.
[36]Pfeffer MA,Braunwald E.Ventricular remodeling after myocardial infarction:experimental observations and clinical implications.Circulation 1990,81:1161-72.
[37]Ho KK,Anderson KM,Kannel WB,Grossman W,Levy D.Survival after the onset of congestive heart failure in Framingham heart study subjects.Circulation 1993,88:107-15.
[38]Redfield MM.Epidemiology and pathophysiology of heart failure.Curr Cardiol Rep 2000,2:179-80.
[39]Edward D.Freis Studies in Hemodynamics and Hypertension.Hypertension 2001,38:1-5.
[40]Frohlich ED.Cardiac hypertrophy in hypertension.N Engl J Med 1987,317:831-833.
[41]Vasan RS,Levy D.The role of hypertension in the pathogenesis of heart failure.A clinical mechanistic overview.Arch Intern Med 1996,156:1789-1796.
[42]Mann DL.Mechanisms and Models in Heart Failure:A Combinatorial Approach Circulation 1999,100:999-1008.
[43]Jessup M,Brozena S.Heart failure.N Engl J Med 2003,348:2007-18.
[44]Iwama H,Amagaya S,Ogihara Y.Effect of shosaikoto,a Japanese and Chinese traditional herbal medical mixture,on the mitogenic activity of lipopolysaccharide:a new pharmacological testing method.J Ethnopharmacol 1987;21(1):45-53
[45]Uneda M,Amagaya S,Ogihara Y Effect of certain herbal medicines on the biotransformation of arachidonic acid:a new pharmacological testing method using serum.J Ethnopharmacol 1988;23(1):91-98
[46]Yutao X,Geru W,Xiaojun B,et al.Mechanical stretch-induced hypertrophy of neonatal rat ventricular myocytes is mediated by beta (1)-integrin-microtubule signaling pathways.Eur J Heart Fail 2006,Jan,8(1):16-22.
[47]Rockman HA,Knowlton KU,Ross J Jr,Chien KR.In vivo murine cardiac hypertrophy:a novel model to identify genetic signaling mechanisms that activate an adaptive physiologic response.Circulation 1993,87 (Suppl.Ⅶ):Ⅶ-14-Ⅶ-21.
[48]Lompre AM,Schwartz K,d'Albis A,Lacombe G,Van Thiem N,Swynghedauw B.Myosin isoenzyme redistribution in chronic heart overload.Nature 1979,282(5734):105-107.
[49]Sealy J,Laragh JH.How to do plasma renin assay.In:Laragh JH,ed.Topics in Hypertension.New York,NY:Yorke Medical Books,1980:244-56.
[50]Dolber PC,Spach MS.Picrosirius red staining of cardiac muscle following phosphomolybdic acid treatment.Stain Technol 1987,62:23-26.
[51]Farrell MH,Foody JM,Krumholz HM.Beta-blockers in heart failure:clinical applications.JAMA 2002,287:890-97.
[52]Nanas JN,Alexopoulos G,Anastasiou-Nana MI,Karidis K,Tirologos A,.Zobolos S.Outcome of patients with congestive heart failure treated with standard versus high doses of enalapril:a Multicenter study.J Am Coll Cardiol 2000,36:2090-95.
[53]Packer M,Poole-Wilson PA,Armstrong PW,et al.Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor,lisinopril,on morbidity and mortality in chronic heart failure.Circulation 1999,100:2312-18.
[54]McMurray J,Pfeffer MA.New Therapeutic Options in Congestive Heart Failure.Circulation 2002,105:2099-06.
[55]Eugene Braunwald,Michael R.Bristow.Congestive Heart Failure:Fifty Years of Progress.Circulation 2000,102:Ⅳ-14-Ⅳ-23.
[56]Grossman W,Jones D,McLaurin LP.Wall stress and patterns of hypertrophy in the human left ventricle.J Clin Invest 1974,56:56-64.
[57]Gerdes AM,Kellerman SE,Moore JA,Muffly KE,Clark LC,Reaves PY,Malec KB,McKeown PP,Schocken DD.Structural remodeling of cardiac myocytes from patients with chronic ischemic heart disease.Circulation 1992,86:426-430.
[1]Abdel-Aleem S,El-Merzanai MM,Sayed-Ahmed M,et aL Acute and chronic effects of doxorubicin on fatty acid oxidation in isolated cardiac myocytes.Journal of Molecular and Cellular Cardiology,1997,29:789-797.
[2]Adams MJ,Lipshultz,SE.Pathophysiology of anthracycline-and radiation-associated cardiomyopathies:implications for screening and prevention.Pediatric Blood and Cancer,2005,44:600-606.
[3]Alderton PM,Gross J,Green MD.Comparative study of doxorubicin,mitoxantrone,and epirubicin in combination with 1CRF-187 (ADR-529)in a chronic cardiotoxicity animal model.Cancer Research,1992,52:194-201.
[4]Anderlini P,Benjamin RS,Wong FC,et al.Idarubicin cardiotoxicity:a retrospective study in acutemyeloid leukemia and myelodysplasia.Journal of Clinical Oncology,1995,13:2827-2834.
[5]Antunes,LM,Takahashi,CS.Protection and induction of chromosomal damage by vitamin C in human lymphocyte cultures.Teratogenesis,Carcinogenesis,and Mutagenesis,1999,19:53-59.
[6]Arai M,Yoguchi A,Takizawa T,et al.Mechanism of doxorubicin-induced inhibition of sarcoplasmatic reticulum Ca2+-ATPase gene transcription.Circulation Research,2000,86:8-14.
[7]Arola OJ,Saraste A,Pulkki K,et al.Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis.Cancer Research,2000,60:1789-1792.
[8]Arrick BA,Nathan CF,Griffith OW,et al.Glutathione depletion sensitizes tumor cells to oxidative cytolysis.The Journal of Biological Chemistry,1982,257:1231-1237.
[9]Batist G,Ramakrishnan G,Rao CS,et al.Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized,multicenter trial of metastatic breast cancer.Journal of Clinical Oncology,2001,19:1444-1454.
[10]Benjamin RS.Rationale for the use of mitoxantrone in the older patient:cardiac toxicity.Seminars of Oncology,1995,22:11-13.
[11]Bhanumathi P,Saleesh EB,Vasudevan DM.Creatinine phosphokinase and cardiotoxicity in doxorubicin chemotherapy and its modification by WR-1065.Biochemical Archives,1992,8:335-338.
[12]Bieber,LL.CarnitinE Annual Review of Biochemistry,1988,57:261-283.
[13]Bleyer W.The impact of childhood cancer on the US and the world.CA:A Cancer Journal for Clinicians,1990,40:355-367.
[14]Boucher F,Coudray C,Tirard V,et al.Oral selenium supplementation in rats reduces cardiac toxicity of doxorubicin during ischemia and reperfusioN Nutrition,1995,11:708-711.
[15]Bozkurt B,Torre-Amione G,Warren MS,et al.Results of targeted antitumor necrosis factor therapy with etanercept (ENBREL)in patients with advanced heart failure.Circulation,2001,103:1044-1047.
[16]Breed JG,Zimmerman AN,Dormans JA,et al.Failure of the antioxidant vitamin E to protect against adriamycininduced cardiotoxicity in the rabbit.Cancer Research,1980,40:2033-2038.
[17]Bristow MR.Mechanisms of action of beta-blocking agents in heart failure.American Journal of Cardiology,1997,80:26L-40L
[18]Bruns LA,Chrisant MK,Lamour JM,et al.Carvedilol as therapy in pediatric heart failure:an initial multicenter experience.Journal of Pediatrics,2001,138:505-511.
[19]Calabro-Jones PM,Aguilera JA,Ward JF,et al.Uptake of WR-2721 derivatives by cells in cultures:identification of the transported form of the drug.Cancer Research,1988,48:3634.
[20]Capizzi R,Oster W.Protection of normal tissue from the cytotoxic effects of chemotherapy and radiation by amifostine:clinical experiences.European Journal of Cancer,1995,31:S8-13.
[21]Carella AM,Berman E,Maraone MP,et al.Idarubicin in the treatment of acute leukemiaS An overview of preclinical and clinical studies.Haematologica,1990,75:159-169.
[22]Carew TE,Schwenke DC,Steinberg D.Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect:evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit.Proceedings of the National Academy of Sciences of the United States of America,1987,84:7725-7729.
[23]Childs AC,Phaneuf SL,Dirks AJ,et al.Doxorubicin treatment in vivo causes cytochrome c release and cardiomyocyte apoptosis,as well as increased mitochondrial efficiency,superoxide dismutase activity,and Bcl-2:Bax ratio.Cancer Research,2002,62:4592-4598.
[24]Ciaccio M,Valenza M,Tesoriere L,et al.Vitamin A inhibits doxorubicin-induced membrane lipid peroxidation in rat tissues in vivo.Archives of Biochemistry and Biophysics,1993,302:103-108.
[25]Ciaccio M,Tesoriere L,Pintaudi AM,et al.Vitamin A preserves the cytotoxic activity of doxorubicin while counteracting its peroxidative effects in human leukemic cells in vitro.Biochemistry and Molecular Biology International,1994,34:329-335.
[26]Cortes EP,Gupta M,Chou C,et al.Doxorubicin cardiotoxicity:early detection by systolic time interval and possible prevention by coenzyme Q10.Cancer Treatment Reports,1978,62:887-891.
[27]Cottin Y,Touzery C,Dalloz F,et al.Comparison of epirubicin and doxorubicin cardiotoxicity induced by low doses:evolution of the diastolic and systolic parameters studies by radionuclide angiography.Clinical Cardiology,1998,21:665-670.
[28]Coudray C,Mouhieddine S,Richard MJ,et al.Effects of doxorubicin on chronic cardiotoxicity in selenium-deficient rats.Basic Research in Cardiology,1992,87:173-183.
[29]Creutzig U,Ritter J,Zimmermann M,et al.Idarubicin improves blast cell clearance during induction therapy in children with AML:results of study AML-BFM 93.AML-BFM Study GrouP Leukemia,2001,15:348-354.
[30]Cvetkovic RS,Scott LJR.Dexrazoxane:a review of its use for cardioprotection during anthracycline chemotherapy.Drugs,2005,65:1005-1024.
[31]D'Aquino M,Dunster C,Willson RL.Vitamin A and glutathione-mediated free radical damage:competing reactions with polyunsaturated fatty acids and vitamin c.Biochemical and Biophysical Research Communications,1989,161:1199-1203.
[32]Danelisen I,Palace V,Lou H,et al.Maintenance of myocardial levels of vitamin A in heart failure due to doxorubicin.Journal of Molecular and Cellular Cardiology,2002,34:789-795.
[33]De Flora S,Bennicelli C,Serra D,et al.Role of glutathione and N-acetylcysteine on the mutagenicity and carcinogenesis.In:Absorption and Utilization of Amino Acids (eD by M Friedman),VoL Ⅲ,1989,19-53.CRC Press,Boca Raton,USA
[34]De Leonardis V,Neri B,Bacalli S,et al.Reduction of cardiac toxicity of anthracyclines by L-carnitine:preliminary overview of clinical data.International Journal of Clinical Pharmacology Research,1985,2:137-142.
[35]De Leonardis V,De Scalzi M,Neri B,et al.Echocardiography assessment of anthracycline cardiotoxicity during different therapeutic regimens.International Journal of Clinical Pharmacology Research,1987,7:307-311.
[36]Deswal A,Bozkurt B,Seta Y,et al.Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel,etanercept)in patients with advanced heart failure.Circulation,1999,99:3224-3226.
[37]Didi M,Didcock E,Davies HA,et al.High incidence of obesity in young adults after treatment of acute lymphoblastic leukemia in childhood.Journal of Pediatrics,1995,127:63-67.
[38]Doba T,Burton GW,Ingold KU.Antioxidant and co-antioxidant activity of vitamin C The effect of vitamin C,either alone or in the presence of vitamin E or a water-soluble vitamin E analogue,upon the peroxidation of aqueous multilamellar phospholipid liposomes.Biochemica and Biophysica Acta,1985,835:298-303.
[39]Doroshow JH,Locker GY,Meyers CE.Enzymatic defenses of the mouse heart against reactive oxygen metabolites Journal of Clinical Investigation,65,128-135.Dorr,RT & Lagel,KE (1994)Anthracycline cardioprotection by amifostine (WR-2721)and its active metabolite (WR-1065)in vitro.Proceedings of the American Society of Clinical Oncology,1980,13:435.
[40]Dorr RT,Shipp NG,Lee KM.Comparison of cytotoxicity in heart cells and tumor cells exposed to DNA intercalating agents in vitro.Anti-Cancer Drugs,1991,2:27-33.
[41]Dragojevic-Simic VM,Dobric SL,Bokonjic DR,et al.Amifostine protection against doxorubicin cardiotoxicity in ratS Anti-Cancer Drugs,2004,15:169-178.
[42]Faber M,Coudray C,Hida H,et al.Lipid peroxidation products,and vitamin and trace element status in patients with cancer before and after chemotherapy,including doxorubiciN A preliminary study.Biological Trace Element Research,1995,47:117-123.
[43]Fassas A,Buffels R,Anagnostopoulos A,et al.Safety and early efficacy assessment of liposomal daunorubicin (DaunoXome)in adults with refractory or relapsed acute myeloblastic leukemia:a phase I-1I studY British Journal of Haematology,2002,116:308-315.
[44]Fazio S,Sabatini D,Capaldo B,et al.A preliminary study of growth hormone in the treatment of dilated cardiomyopathy.The New England Journal of Medicine,1996,334:809-814.
[45]Fazio S,Palmieri EA,Ferravante B,et al.Doxorubicin-induced cardiomyopathy treated with carvedilol.Clinical Cardiology,1998,21:777-779.
[46]Ferrari R,Ceconi C,Curello S.Oxygen free radicals and myocardial damage:protective role of thiol-containing agents.American Journal of Medicine,1991,91:95S-105S
[47]Ferrari R,Bachetti T,Confortini R,et al.Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure.Circulation,1995,92:1479-1486.
[48]Feuerstein GZ,Ruffolo RR.Carvedilol,a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection.European Heart Journal,1995,16:38-42.
[49]Fisher PW,Salloum R,Das A,et al.Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity.Circulation,2005,111:1601-1610.
[50]Folkers K,Choe JY,Combs AB.Rescue by coenzyme Q10 from electrocardiographic abnormalities caused by the toxicity of doxorubicin in the rat.Proceedings of the National Academy of Sciences of the United States of America,1978,75:5178-5180.
[51]Folkers K,Brown R,Judy WV,et al.Survival of cancer patients on therapy with coenzyme Q10.Biochemical and Biophysical Research Communications,1993,192:241-245.
[52]Frei,B.Reactive oxygen species and antioxidant vitamins:mechanisms of action.American Journal of Medicine,1994,97:5S-13S
[53]Frishman WH.CarvediloL Drug Therapy,1998,24:1759-1765.
[54]Gabizon AA.Liposomal anthracyclines.Hematology/Oncology Clinics of North America,1994,8:431-450.
[55]Ganzina F.4 (?)-epi-doxorubicin,a new analogue of doxorubicin:a preliminary overview of preclinical and clinical data.Cancer Treatment Reviews,1983,10:1-22.
[56]Ganzina F,Di Pietro N,Magni O.Clinical toxicity of 4 (?)-epi-doxorubicin (epirubicin).Tumori,1985,71:233-240.
[57]Gatta G,Capocaccia R,Coleman MP,et al.Childhood cancer survival in Europe and the United States.Cancer,2002,95:1767-1772.
[58]Geetha A,Catherine J,Shyamala Devi CS.Effect of alphatocopherol on the microsomal lipid peroxidation induced by doxorubicin:influence of ascorbic acid.Indian Journal of Physiological Pharmacology,1989,33:53-58.
[59]Gewirtz DA.A Critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics doxorubicin and daunorubicin.Biochemical Pharmacology,1999,57:727-741.
[60]Gianni L,Zweier J,Levy A,et al.Characterization of the cycle of iron-mediated electron transfer from doxorubicin to molecular oxygen.Journal of Biological Chemistry,1985,259:6056-6058.
[61]Giantris A,Abdurrahman L,Hinkle A,et al.Anthracycline-induced cardiotoxicity in children and young adults.Critical Reviews in Oncology/Hematology,1998,27:53-68.
[62]Gill PS,Wernz J,Scadden DT.Randomized phase 111 trial of liposomal daunorubicin versus doxorubicin,bleomycin,and vincristine in AlDS-related Kaposi's sarcoma.Journal of Clinical Oncology,1996,14:2353-2364.
[63]Glover D,Glick JH,Weiler C,et al.Phase Ⅰ/Ⅱ trials of WR-2721 and cis-platinum.International Journal of Radiation Oncology Biology Physics,1986,12:1509-1512.
[64]Goldhaber SB.Trace element risk assessment:essentiality vS toxicity.Regulatory Toxicology and Pharmacology,2003,38:232-242.
[65]Goormaghtigh E,Huart P,Praet M,et al.Structure of the doxorubicin-cardiolipin complex role in mitochondrial toxicity.Biophysical Chemistry,1990,35:247-257.
[66]Green DM,Hyland A,Chung CS,et al.Cancer and cardiac mortality among 15-year survivors of cancer diagnosed during childhood or adolescence.Journal of Clinical Oncology,1999,17,3207-3215.
[67]Green DM,Grigoriev YA,Nan B,et al.Congestive heart failure after treatment for Wilms' tumor:a report from the National Wilms' Tumor Study Group.Journal of Clinical Oncology,2001,19:1926-1934.
[68]Grenier MA,Lipshultz SE.Epidemiology of anthracycline cardiotoxicity in children and adults.Seminars in Oncology,1998,25:72-85.
[69]Halliwell B.Vitamin C:antioxidant or pro-oxidant in vivo.Free Radical Research,1996,25: 439-454.
[70]Hailiwell B,Gutteridge JMC.Antioxidant protection by low-molecular-mass agents:compounds derived from the dieT In:Free Radicals in Biology and Medicine (eD by B Hailiwell & JMC Gutteridge),1999,200-217.Oxford University Press,New York,USA
[71]Haq MM,Legha SS,Choksi J,et al.Doxorubicin-induced congestive heart failure in adults.Cancer,1985,56:1361-1365.
[72]Harris L,Batist G,Belt R,et al.Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma.Cancer,2002,94:25-36.
[73]Hasinoff BB.The interaction of the cardioprotective agent ICRF-187 [+)-l,2-bis(3,5-dioxopiperazinyl-l-yL)propane);its hydrolysis product (ICRF-198);and other chelating agents with the Fe(Ⅲ)and Cu(Ⅱ)complexes of doxorubicin.Agents Actions,1989,26:378-385.
[74]Heidenreich PA,Lee TT,Massie BM.Effect of betablockade on mortality in patients with heart failure:a meta-analysis of randomized clinical trials.Journal of American College of Cardiology,1997,30:27-34.
[75]Herman EH,Ferrans VJ.Reduction of chronic doxorubicin cardiotoxicity in dogs by pretreatment with (+/))-l,2-bis (3,5-dioxopipreazine-l-yl)propane (ICRF-187).Cancer Research,1981,41:3436-3440.
[76]Herman EH,Ferrans VJ,Young RS,et al.Effect of pretreatment with ICRF-187 on the total cumulative dose of doxorubicin tolerated by beagle dogs.Cancer Research,1988,48:6918-6925.
[77]Herman EH,Zhang J,Hasinoff BB,et al.Comparison of the structural changes induced by doxorubicin and mitoxantrone in the heart,kidney and intestine and characterization of the Fe(Ⅲ)-mitoxantrone complex.Molecular and Cellular Cardiology,1997a,29:2415-2430.
[78]Herman EH,Zhang J,Hasinoff BB,et al.Comparison of the protective effects against chronic doxorubicin cardiotoxicity and the rates of iron (Ⅲ)displacement reactions of ICRF-187 and other bisdiketopiperazines.Cancer Chemotherapy and Pharmacology,1997b,40:400-408.
[79]Herman EH,Zhang J,Chadwick DP,et al.Comparison of the protective effects of amifostine and dexrazoxane against the toxicity of doxorubicin in spontaneously hypertensive rats.Cancer Chemotherapy and Pharmacology,2000,45:329-334.
[80]Herman EH,Zhang J,Rifai N,et al.The use of serum levels of cardiac troponinTto compare the protective activity of dexrazoxane against doxorubicin-and mitoxantrone-induced cardiotoxicity.Cancer Chemotherapy and Pharmacology,2001,48:297-304.
[81]Hinkle AS,Proukou CB,Deshpande SS,et al.Cardiotoxicity caused by chemotherapY In:Late Effects of Childhood Cancer (eD by WHB Wallace & DM Green),2004a,85-100.Edward Arnold,New York,USA
[82]Hinkle AS,Proukou C,French CA,et al.A clinicbased,comprehensive care model for studying late effects in longterm survivors of pediatric illnesses.Pediatrics,2004b,113:1141-1145.
[83]Hortobagyi GN,Frye D,Buzdar AU,et al.Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma.Cancer,1989,63:37-45.
[84]larussi D,Auricchio U,Agretto A,et al.Protective effect of coenzyme Q10 on anthracyclines cardiotoxicity:control study in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma.Molecular Aspects of Medicine,1994,15:207-212.
[85]lliskovic N,Singal PK.Lipid lowering:an important factor in preventing doxorubicin-induced heart failure.American Journal of Pathology,1997,150:727-734.
[86]lliskovic N,Hasinoff BB,Malisza KL,et al.Mechanisms of beneficial effects of probucol in doxorubicin cardiomyopathy.Molecular and Cellular Biochemistry,1999,196:43-49.
[87]Institute of Medicine,Food and Nutrition Board (2001)Dietary Reference Intakes:Vitamin A,Vitamin K,Arsenic,Boron,Chromium,Copper,Iodine,Iron,Manganese,Molybdenum,Nickel,Silicon,Vanadium,and Zinc.National Academy Press,Washington,DC,USA
[88]Isgaard J,Bergh CH,Caidahl K,et al.A placebo-controlled study of growth hormone in patients with congestive heart failure.European Heart Journal,1998,19:1704-1711.
[89]Iwamoto Y,Yamagami T,Folkers K.Deficiency of coen2yme Q10 in hypertensive rats and reduction of deficiency by treatment with coenzyme Q10.Biochemical and Biophysical Research Communications,1974,58:743-748.
[90]Jeyaseelan R,Poizat C,Wu HY,et al.Molecular mechanisms of doxorubicin-induced cardiomyopathY Selective suppression of Reiske iron-sulfur protein,ADP/ATP translocase,and phosphofructokinase genes is associated with ATP depletion in rat cardiomyocytes.Journal of Biological Chemistry,1997,272:5828-5832.
[91]Kishi T,Folkers K.Prevention by coenzyme Q10 of the inhibition by doxorubicin of coenzyme Q10-enzymes.Cancer Treatment Reports,1976,60:223-224.
[92]Klein S,Burke LE,Bray GA,et al.Clinical implications of obesity with specific focus on cardiovascular disease:a statement for professionals from the American Heart Association Council on Nutrition,Physical Activity,and Metabolism:endorsed by the American College of Cardiology Foundation.Circulation,2004,110:2952-2967.
[93]Kremer LCM,van Dalen EC,Offringa M,et al.AnthracycHne-induced clinical heart failure in a cohort of 607 children:long-term follow-up study.Journal of Clinical Oncology,2001,19:191-196.
[94]Kremer LCM,van der Pal HJ,Offringa M,et al.Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children:a systematic review.Annals of Oncology,2002,13:819-829.
[95]Kn'nsky NI.Mechanisms of carotenoids in biological systems.Annual Review of Nutrition,1993,13:561-587.
[96]Krischer JP,Epstein S,Cuthbertson DD,et al.Clinical cardiotoxicity following anthracycline treatment for childhood cancer:the Pediatric Oncology Group Experience.Journal of Clinical Oncology,1997,15:1544-1552.
[97]Kurbacher CM,Wagner U,Kolster B,et al.Ascorbic acid (vitamin C)improves the antineoplastic activity of doxorubicin,cisplatin,and paclitaxel in human breast carcinoma cells in vitro.Cancer Letters,1996,103:183-189.
[98]Kuzuya M,Kuzuya F.Probucol as an antioxidant and antiatherogenic drug.Free Radical Biology and Medicine,1993,14:67-77.
[99]Lahtinen R,Kuikka J,Nousiainene T,et al.Cardiotoxicity of epirubicin and doxorubicin:a double-blind randomized study.European Journal of Haematology,1991,46:301-305.
[100]Lebrecht DMS,Setzer B,Ketelsen UP,et al.Time-dependant and tissue-specific accumulation of mtDNA and respiratory chain defects in chronic doxorubicin cardiomyopathy.Circulation,2003,108:2423-2429.
[101]Lechat P,Packer M,Chalon S,et al.Clinical effects of beta-adrenergic blockade in chronic heart failure:a meta-analysis of double-blind,placebo-controlled,randomized trials.Circulation,1998,98:1184-1191.
[102]Lefrak EA,Pitha J,Rosenheim S,et al.A clinicopathologic analysis of doxorubicin cardiotoxicity.Cancer,1973,32:302-314.
[103]Legha SS,Benjamin RS,Mackay B,et al.Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion.Annals of Internal Medicine,1982,96:133-139.
[104]Levitt GA,Dorup I,Sorensen K,et al.Does anthracycline administration by infusion in children affect late cardiotoxicity.British Journal of Haematology,2004,124:463-468.
[105]Li T,Singal PK.Doxorubicin-induced early changes in myocardial antioxidant enzymes and their modulation by probucol.Circulation,2000,102:2105-2110.
[106]Li T,Danelisen I,Bello'-Klein A,et al.Effects of probucol on changes of antioxidant enzymes in doxorubicin-induced cardiomyopathy in rats.Cardiovascular Research,2000,46:523-530.
[107]Lipshultz SE,Colan SD,Gelber RD,et al.Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood.The New England Journal of Medicine,1991,324:808-815.
[108]Lipshultz SE,Lipsitz SR,Mone SM,et al.Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer.The New England Journal of Medicine,1995,332:1556-1738.
[109]Lipshultz SE,Giantris AL,Lipsitz SR,et al.Doxorubicin administration by continuous infusion is not cardioprotective:the Dana-Farber 91-01 acute lymphoblastic leukemia protocol.Journal of Clinical Oncology,2002a,20:1677-1682.
[110]Lipshultz SE,Lipsitz SR,Sallan SE,et al.Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer.Journal of Clinical Oncology,2002b,20:4517-4522.
[111]Lipshultz SE,Rifai N,Dalton VM,et al.The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia.The New England Journal of Medicine,2004a,351:145-153.
[112]Lipshultz SE,Colan SD.Cardiovascular trials in longterm survivors of childhood cancer.Journal of Clinical Oncology,2004b,22:769-773.
[113]Lipshultz SE,Lipsitz SR,Sallen SE,et al.Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia.Journal of Clinical Oncology,2005a,23:2629-2636.
[114]Lipshultz SE,Vlach SA,Lipsitz SR,et al.Cardiac changes associated with growth hormone therapy among children treated with anthracyclines.Pediatrics,2005b,115:1613-1622.
[115]Livrea MA,Tesoriere L,Bongiorno A,et al.Contribution of vitamin A to the oxidation resistance of human low density lipoproteins.Free Radical Biology and Medicine,1995,18:401-409.
[116]Lopez M,Vici P,Di Lauro L,et al.Randomized prospective clinical trial to evaluate cardio-protection of dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas.Journal of Clinical Oncology,1998,16:86-92.
[117]Lu J,Jiang C,Kaeck M,et al.Cellular and metabolic effects of triphenylselenonium chloride in a mammary cell culture model.Carcinogenesis,1995,16:513-517.
[118]Matsuda A,Kimura M,Itokawa Y.Influence of selenium deficiency on the acute cardiotoxicity of doxorubicin in rats.Biological Trace Element Research,1997,57:157-167.
[119]Matsui H,Morishima 1,Numaguchi Y,et al.Protective effects of carvedilol against doxorubicin-induced cardiomyopathy in rats.Life Sciences,1999,65:1265-1274.
[120]Meister A.Selective modification of glutathione metabolism.Science,1983,220:472-477.
[121]Mertens AC,Yasui Y,Neglia JP,et al.Late mortality experience in five-year survivors of childhood and adolescent cancer:the Childhood Cancer Survivor Study.Journal of Clinical Oncology,2001,19:3163-3172.
[122]Meyers CE,McGuire WP,Liss RH,et al.Adriamycin:the role of lipid peroxidation in cardiac toxicity and tumor response.Science,1977,197:165-167.
[123]Miller TL,Horgan S,Lipshultz SE.Exercise rehabilitation of pediatric patients with cardiovascular diseasE Progress in Pediatric Cardiology,2005,20:27-37.
[124]Mohamed HE,El-Swefy SE,Hagar HH.The protective effect of glutathione administration on doxorubicin-induced acute cardiac toxicity in rats.Pharmacological Research,2000,42:115-121.
[125]Mo'ller TR,Garwicz S,Barlow L,et al.Decreasing late mortality among five-year survivors of cancer in childhood and adolescence:a population-based study in the Nordic countries.Journal of Clinical Oncology,2001,19:3173-3181.
[126]Money-Kyrle JF,Bates F,Ready J,et al.Liposomal daunorubicin in advanced Kaposi's sarcoma:a phase Ⅱ study.Clinical Oncology (Royal College of Radiologists),1993,5:367-371.
[127]Moran AM,Colan SD,Majzoub JA,et al.Exogenous growth hormone:a new therapy for dilated cardiomyopathy.Progress in Pediatric Cardiology,2000,12:125-132.
[128]Myers CE,Bonow R,Palmeri S,et al.A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine.Seminars in Oncology,1983,10:53-55.
[129]Nazeyrollas P,Frances C,Prevost A,et al.Efficiency of amifostine as a protection against doxorubicin toxicity in rats during a 12-day treatment.Anticancer Research,2003,23:405-409.
[130]Noguchi N,Nishino K,Niki,E.Antioxidant action of the antihypertensive drug,carvedilol,against lipid peroxidation.Biochemical Pharmacology,2000,59:1069-1076.
[131]Nysom K,Colan DC,Lipshultz SE.Late cardiotoxicity following anthracycline therapy for childhood cancer.Progress in Pediatric Cardiology,1998a,8:121-138.
[132]Nysom K,Holm K,Lipsitz SR,et al.Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia.Journal of Clinical Oncology,1998b,2:545-550.
[133]O'Brien ME,Wigler N,Inbar M,et al.Reduced cardiotoxicity and comparable efficacy in a phase Ⅲ trial of pegylated liposomal doxorubicin HC1 (CAELYX/Doxil)versus conventional doxorubicin for first-line treatment of metastatic breast cancer.Annals of Oncology,2004,15:440-449.
[134]O'Byrne KJ,Thomas AL,Sharma RA,et al.A phase I dose-escalating study of DaunoXome,liposomal daunorubicin,in metastatic breast cancer.British Journal of Cancer,2002,87:15-20.
[135]Okuma K,Furuta 1,Ota K.Protective effect of coenzyme Q10 in cardiotoxicity induced by doxorubicin.Gan To Kagaku Ryoho,1984,11:502-508.
[136]Olson R,Mushlin P.Doxorubicin cardiotoxicity:analysis of prevailing hypothesis.FASEB Journal,1990,4:3076-3086.
[137]Osterziel KJ,Strohm O,Schuler J,et al.Randomized,double-blind,placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy.The Lancet,1998,351:1233-1237.
[138]Perego P,Corna E,De Cesare M,et al.Role of apoptosis and apoptosisrelated genes in cellular response and antitumor efficacy of anthracyclines.Current Medicinal Chemistry,2001,8:31-37.
[139]Perez DJ,Harvey VJ,Robinson BA,et al.A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer.Journal of Clinical Oncology,1991,9:2148-2152.
[140]Perrot A,Ranke MB,Dietz R,et al.Growth hormone treatment in dilated cardiomyopathy.Journal of Cardiac Surgery,2001,16:127-131.
[141]Pfeffer MA,Braunwald E,Moye LA,et al.Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction:results of the survival and ventricular enlargement trial-the SAVE Investigators.The New England Journal of Medicine,1992,327:669-677.
[142]Platel D,Pouna P,Bonoron-Adele S,et al.Comparative cardiotoxicity of idarubicin and doxorubicin using the isolated perfused rat heart model.Anti-Cancer Drugs,1999,10:671-676.
[143]Quiles JL,Huertas JR,Battino M,et al.Antioxidant nutrients and doxorubicin toxicity.Toxicology,2002,180:79-95.
[144]Redfield MM,Gersh BJ,Bailey KR,et al.Natural history of incidentally discovered asymptomatic idiopathic dilated cardiomyopathy.American Journal of Cardiology,1994,74:737-739.
[145]Rodvold KA,Rushing DA,Tewksbury DA.Doxorubicin clearance in the obese,Journal of Clinical Oncology,1988,6:1321-1327.
[146]Ryberg M,Nielsen D,Skovsgaard T,et al.Epirubicin cardiotoxicity:an analysis of 469 patients with metastatic breast cancer.Journal of Clinical Oncology,1998,16:3502-3508.
[147]Safra T.Cardiac safety of liposomal anthracyclines.The Oncologist,2003,8:17-24.
[148]Sallan SE,Lipshultz SE.Wise up:don't do it without protectioN Pediatric Blood and Cancer,in press Sayed-Ahmed,MM,Salman,TM,Gaballah,HE,Abou El Naga,SA,Nicolai,R & Calvani,M (2001)Propionyl-L-carnitine as protector against doxorubicin-induced cardiomyopathy.Pharmacological Research,2005,43:513-520.
[149]Schuchter LM,Hensley ML,Meropol NJ,et al.Update of recommendations for the use of chemotherapy and radiotherapy protectants:clinical practice guidelines of the American Society of Clinical Oncology.Journal of Clinical Oncology,2002,20:2895-2903.
[150]Seta Y,Shan K,Bozkurt B,et al.Basic mechanisms in heart failure:the cytokine hypothesis.Journal of Cardiac Failure,1996,2:243-249.
[151]Shaddy RE,Tani LY,Gidding SS,et al.Beta-blocker treatment of dilated cardiomyopathy with congestive heart failure in children:a multiinstirutional experience.Journal of Heart and Lung Transplantation,1999,18:269-274.
[152]Shapira J,Gotfried M,Lishner M,et al.Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen:a prospective randomized evaluation.Cancer,1990,65:870-873.
[153]Shimpo K,Nagatsu T,Yamada K,et al.Ascorbic acid and doxorubicin toxicity.American Journal of Clinical Nutrition,1991,54:1298S-1301S
[154]Silber JH,Cnaan A,Clark BJ,et al.Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines.Journal of Clinical Oncology,2004,22:820-828.
[155]Simbre VC Ⅱ,Adams MJ,Deshpande SS,et al.Cardiomyopathy caused by antineoplastic therapies.Current Treatment Options in Cardiovascular Medicine,2001,3:493-505.
[156]Simbre VC Ⅱ,Duffy SA,Dadlani GH,et al.Cardiotoxicity of cancer chemotherapy:implications for children.Pediatric Drugs,2005,7:187-202.
[157]Singal PK,Iliskovic N.Doxorubicin-induced cardiomyopathy.The New England Journal of Medicine,1998,339:900-905.
[158]Singal PK,Deally CM,Weinberg LE.Subcellular effects of doxorubicin in the heart.A concise revieW Journal of Molecular and Cellular Cardiology,1987,19:817-828.
[159]Siveski-Iliskovic N,Hill M,Chow DA,et al.Probucol protects against doxorubicin cardiomyopathy without interfering with its antitumor effect.Circulation,1995,91:10-15.
[160]Skudicky D,Sliwa K,Bergemann A,et al.Reduction in Fas/Apo-1 plasma concentrations correlates with improvement in left ventricular function in patients with idiopathic dilated cardiomyopathy treated with Pentoxifylline.Heart,2000,84:438-441.
[161]Skudicky D,Bergemann A,Sliwa K,et al.Beneficial effects of pentoxifylline in patients with idiopathic dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitors and carvedilol:results of a randomized study.Circulation,2001,103:1083-1088.
[162]Slamon D.Pegram M.Rationale for trastuzumab (Herceptin)in adjuvant breast cancer trials.Seminars in Oncology,2001,28:13-19.
[163]Sliwa K,Woodiwiss A,Candy G,et al.Effects of pentoxifylline on cytokine profiles and left ventricular performance in patients with decompensated congestive heart failure secondary to idiopathic dilated cardiomyopathy.American Journal of Cardiology,2002,90:1118-1122.
[164]Sorensen K,Levitt G,Sebag Montefiore D,et al.Cardiac function in Wilms' tumor survivors.Journal of Clinical Oncology,1995,13:1546-1556.
[165]Sorensen K,Levitt G,Bull C,et al.Anthracycline dose in childhood acute lymphoblastic leukemia:issues of early survival versus late cardiotoxicity.Journal of Clinical Oncology,1997,15:61-68.
[166]Sorensen K,Levitt GA,Bull C,et al.Late anthracycline cardiotoxicity after childhood cancer.Cancer,2003,97:1991-1998.
[167]Spallarossa P,Garibaldi S,Altieri P,et al.Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro.Journal of Molecular and Cellular Cardiology,2004,37:837-846.
[168]Speyer JL,Green MD,Zeleniuch-Jacquotte A,et al.ICRF-187 permits longer treatment with doxorubicin in women with breast cancer.Journal of Clinical Oncology,1992,10:117-127.
[169]Steinherz LJ,Steinherz PG,Tan CT,et al.Cardiac toxicity 4 to 20 years after completing anthracycline therapy.JAMA,1991,266:1672-1677.
[170]Sugino K,Dohi K,Yamada K,et al.The role of lipid peroxidation in endotoxin-induced hepatic damage and the protective effect of antioxidants.Surgery,1987,101:746-752.
[171]Suttorp N,Toepfer W,Roka,L.Antioxidant defense mechanisms of endothelial cells:glutathione redox cycle versus catalase.American Journal of Physiology,1986,251:671-680.
[172]Swain SM,Whaley FS,Gerber MC,et al.Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.Journal of Clinical Oncology,1997a,15:1318-1332.
[173]Swain SM,Whaley FS,Gerber MC,et al.Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy.Journal of Clinical Oncology,1997b,15:1333-1340.
[174]Swain SM,Whaley FS,Ewer MS.Congestive heart failure in patients treated with doxorubicin:a retrospective analysis of three trials Cancer,2003,97:2869-2879.
[175]Takabe W,Kodama T,Hamakubo T,et al.Anti-atherogenic antioxidants regulate the expression and function of protea-some alpha-type subunits in human endothelial cells.Journal of Biological Chemistry,2001,44:40497-40501.
[176]Tardi PG,Boman NL,Cullis PR.Liposomal doxorubicin.Journal of Drug Targeting,1996,4:129-140.
[177]The American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure)Guidelines for the evaluation and management of heart failurE Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure).Circulation,1995,92:2764-2784.
[178]The SOLVD Investigators.Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.The New England Journal of Medicine,1991,325:293-302.
[179]The SOLVD Investigators.Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions.The New England Journal of Medicine,1992,327:685-691.
[180]The SOLVD Investigators.Effects of long-term enalapril therapy on left ventricular diastolic properties in patients with depressed ejection fraction.Circulation,1993,88:481-491.
[181]Thuesen L,Christiansen JS,Sorensen KE,et al.P Increased myocardial contractility following growth hormone administration in normal man.An echocardiographic studY Danish Medical Bulletin,1988,35:193-196.
[182]Torre-Amione G,Kapadia S,Benedict CR,et al.Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction:a report from the studies of left ventricular dysfunction (SOLVD).Journal of the American College of Cardiology,1996,27:1201-1206.
[183]Traber MG,Packer L.Vitamin E:beyond antioxidant function.American Journal of Clinical Nutrition,1995,62:1501-1509.
[184]Unverferth DV,Unverferth BJ,Balcerzak SP,et al.Cardiac evaluation of mitoxantrone.Cancer Treatment Reports,1983,67:343-350.
[185]Van Vleet JF,Greenwood L,Ferrans VJ,et al.Effect of selenium-vitamin E on doxorubicin-induced cardiomyopathy in rabbits.American Journal of Veterinary Research,1978,39:997-1010.
[186]Van Vleet JF,Ferrans VJ,Weirich WE.Cardiac disease induced by chronic doxorubicin administration in dogs and an evaluation of vitamin E and selenium as cardioprotectants.American Journal of Pathology,1980,99:13-42.
[187]Venturini M,Michelotti A,Del Mastro L,et al.Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer.Journal of Clinical Oncology,1996,14:3112-3120.
[188]Volterrani M,Desenzani P,Lorusso R,et al.Haemodynamic effects of intravenous growth hormone in congestive heart failure.The Lancet,1997,349:1067-1068.
[2]McNeil AR,Blok BH,Koelmeyer TD,et al.Phaeochromocytomas discovered during coronial autopsies in Sydney,Melbourne and Auckland.Aust NZ J Med,2000,30:648-652.
[3]John H,Ziegler WH,Hauri D,et al.Pheochromocytomas:can malignant potential be predicted? Urology,1999,53:679-683.
[4]Mundschenk J,Lehnert H.Malignant pheochromocytoma.Exp Clin Endocrinol Diabetes.1998,106:373-376.
[5]Lin DD,Loughlin KR.Diagnosis and management of surgical adrenal diseases.Urology,2005,66:476-483.
[6]Amar L,Servais A,Gimenez-Roqueplo AP,et al.Year of diagnosis,features at presentation,and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma.J Clin Endocrinol Metab,2005,90:2110-2116.
[7]Grumbach MM,Biller BM,Braunstein GD,et al.Management of the clinically inapparent adrenal mass (“incidentaloma” ).Ann Intern Med,2003,138:424-429.
[8]Mannelli M,lanni L,Cilotti A,et al.Pheochromocytoma in Italy:A multicentric retrospective study.Eur J Endocrinol,1999,141:619-624.
[9]Mantero F,Terzolo M,Arnaldi G,et al.A survey on adrenal incidentaloma in Italy.Study Group on Adrenal Tumors of the Italian Society of Endocrinology.J Clin Endocrinol Metab,2000,85:637-644.
[10]Kasperlik-Zaluska AA,Roslonowska E,Slowinska-Srzednicka J,et al.1111 Patients with adrenal incidentalomas observed at a single endocrinological center:Incidence of chromaffin tumors.Ann NY Acad Sci,2006,1073:38-46.
[11]Whalen RK,AlthausenAF,Daniels GH.Extra-adrenal pheochromocytoma.J Urol,1992,147:1-10.
[12]Pacak K,LinehanWM,EisenhoferG,et al.Recent advances in genetics,diagnosis,localization,and treatment of pheochromocytoma.Ann Intern Med,2001,134:315-329.
[13]郑德裕,佟万仁,惠汝太。继发性高血压诊断治疗学。人民军医出版社,北京,2005年9月第l版。
[14]Lenders J H,Pacak K,Halther MM,et al.Biochemical diagnosis of pheochromocytoma:which test is best? JAMA,2002,287:1427-1434.
[15]Eisenhofer G.Free or total metanephrines for diagnosis of pheochromocytoma:what is the difference? Clin Chem,2001,47:988-998.
[16]Roden M.How to detect pheochromocytomas?—the diagnostic relevance of plasma free metanephrines.Hien Klin Hochenschr,2002,114:246-251.
[17]Eisenbofer G,Keiser HR,Friberget P,et al.Plasma metanephrines are markers of pheochromocytoma produced by catechol-O-methyltransferase within tumors? J Clin Endocrinol Metab,1998,83:2175-2185.
[18]Raber W,Raffesberg W,Bischof M,et al.Diagnostic efficacy of unconjugated plasma metanephrines for the detection of pheochromocytoma.Arch Intern Med,2000,160:2957-2963.
[19]Pacak K,Goldstein D,Doppman J,et al.A "Pheo" lurks:novel approaches for locating occult pheochromocytoma.J Clin Endocrinal Metab,2001,86:3641-3646.
[20]Hoizey G,Lucas CC,Frances C,et al.Study of diurnal fluctuations of plasma methoxyamines in healthy volunteers.Clin Endocrinal (Oxf),2002,56:119-122.
[21]Molnar I,Horvath C.Reverse-phase chromatography of polar biological substances:separation of catechol compounds by high-performance liquid chromatography.Clin Chem,1976,22(9):1497-1502.
[22]Shoup RE,Kissinger PT.Determination of urinary normetanephrine,metanephrine,and 3-methoxytyramine by liquid chromatography,with amperometric detection.C]in Chem,1977,23(7):1268-1274.
[23]Peterson ZD,Collins DC,Bowerbank CR,et al.Determination of catecholamines and metanephrines in urine by capillary electrophoresis-electrospray ionization-time-of-flight mass spectrometry.J Chromatogr B Analyt Technol Biomed Life Sci,2002,776(2):221-229.
[24]Claver Canfell,Steven R.Quantitation of Urinary Normetanephrine and Metanephrine by Reversed-Phase Extraction and Mass-Fragment ographic Analysis.Clin Chem,1982,28(1):25-28.
[25]Wolthers BG,Kema IP,Volmer M,et al.Evaluation of urinary metanephrine and normetanephrine enzyme immunoassay (ELISA)kits by comparison with isotope dilution mass spectrometry.Clin Chem,1997,43(1):114-120.
[26]Karel Pacak,Graeme Eisenhofer,Hakan Ahlman,et al.Pheochromocytoma:recommendations for clinical practice from the First International Symposium.Nature Clinical Practice Endocrinology & Metabolism,2007,3(2):92-102.
[27]Nancy C.Parker,Cyndy B.Levtzow,Patricia W.Wright,et al.Uniform Chromatographic Conditions for Quantifying Urinary Catecholamines,Metanephrines,VaniHylmandelic Acid,5-Hydroxyindoleacetic Acid,by Liquid Chromatography,with Electrochemical Detection.Clin Chem,1986,32(8):1473-1476.
[28]Paul H.Gamache,Manning L.Kingery and Ian N.Acworth.Urinary Metanephrine and Normetanephrine Determined without Extraction by Using Liquid Chromatography and Coulometric Array Detection.Clin Chem,1993,39(9):1825-1830.
[29]Paul J.Orsulak,Patricia Kizuka,Edwin Grab,et al.Determination of Urinary Normetanephrine and Metanephrine by Radial-Compression Liquid Chromatography and Electrochemical Detection.Clin Chem,1983,29(2):305-309.
[30]James G.Flood and Robert B.McComb.Urinary Metanephrines as Measured by Liquid Chromatography with an 0n-Line Post-Column Reaction Detector.Clin Chem,1981,27(7):1268-1271.
[31]Willemsen JJ,Sweep CG,Lenders JW,et al.Stability of Plasma Free Metanephrines during Collection and Storage as Assessed by an Optimized HPLC Method with Electrochemical Detection,Clin Chem,2003,49(11):1951-1953.
[32]Willemsen JJ,Ross HA,Lenders WM,et al.Stability of urinary fractionated metanephrines and catecholamines during collection,shipment and storage of samples.Clin Chem,2007,53:268-272.
[1]Moser M,Setaro JF.Resistant or difficult-to-control hypertension.N Engl J Med,2006,355:385-392.
[2]McNeil AR,Blok BH,Koelmeyer TD,et al.Phaeochromocytomas discovered during coronial autopsies in Sydney,Melbourne and Auckland.Aust NZ J Med,2000,30:648-652.
[3]John H,Ziegler WH,Hauri D,et al.Pheochromocytomas:can malignant potential be predicted? Urology,1999,53:679-683.
[4]Mundschenk J,Lehnert H.Malignant pheochromocytoma.Exp Clin Endocrinol Diabetes.1998,106:373-376.
[5]Lin DD,Loughlin KR.Diagnosis and management of surgical adrenal diseases.Urology,2005,66:476-483.
[6]Amar L,Servais A,Gimenez-Roqueplo AP,et al.Year of diagnosis,features at presentation,and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma.J Clin Endocrinol Metab,2005,90:2110-16.
[7]Grumbach MM,Biller BM,Braunstein GD,et al.Management of the clinically inapparent adrenal mass (“incidentaloma”).Ann Intern Med,2003,138:424-429.
[8]Mannelli M,Ianni L,Cilotti A,et al.Pheochromocytoma in Italy:A multicentric retrospective study.Eur J Endocrinol,1999,141:619-624.
[9]Mantero F,Terzolo M,Arnaldi G,et al.A survey on adrenal incidentaloma in Italy.Study Group on Adrenal Tumors of the Italian Society of Endocrinology.J Clin Endocrinol Metab,2000,85:637-644.
[10]Kasperlik-Zaluska AA,Roslonowska E,Slowinska-Srzednicka J,et al.1111 Patients with adrenal incidentalomas observed at a single endocrinological center:Incidence of chromaffin tumors.Ann NY Acad Sci,2006,1073:38-46.
[11]Whaien RK,Althausen AF,Daniels GH.Extra-adrenal pheochromocytoma.J Urol,1992,147:1-10.
[12]Pacak K,Linehan WM,Eisenhofer G,et al.Recent advances in genetics,diagnosis,localization,and treatment of pheochromocytoma.Ann Intern Med,2001,134:315-29.
[13]Lenders JW,Eisenhofer G,Mannelli M,et al.Phaeochromocytoma.Lancet,2005,366:665-675.
[14]Eisenhofer G,Kopin IJ,Goldstein DS.Catecholamine metabolism:A contemporary view with implications for physiology and medicine.Pharmacol Rev,2004b,56:331-349.
[15]Willemsen JJ,Sweep CG,Lenders JW,et al.Stability of Plasma Free Metanephrines during Collection and Storage as Assessed by an Optimized HPLC Method with Electrochemical Detection,Clinical Chemistry,2003,49(11):1951-1953.
[16]Willemsen JJ,Ross HA,Lenders WM,et al.Stability of urinary fractionated metanephrines and catecholamines during collection,shipment and storage of samples.Clin Chem,2007,53:268-272.
[17]Lenders JW,Pacak K,Walther MM,et al.Biochemical diagnosis of pheochromocytoma:Which test is best? JAMA,2002,287:1427-1434.
[18]Karel Pacak,Graeme Eisenhofer,Hakan Ahlman,et al.Pheochromocytoma:recommendations for clinical practice from the First International Symposium.Nature Clinical Practice Endocrinology & Metabolism,2007,3(2):92-102.
[19]Richard MB,Denise ML,Stephen B.Plasma catecholamine and nephrine responses to brief intermittent maximal intensity exercise.Amino Acids,spriger.2008,36(2):209-217.
[20]Mazza A,Zamboni S,Armigliato M,et al.Endocrine arterial hypertension:diagnostic approach in clinical practice.Minerva Endocrinol,2008,33:127-146.
[21]Eisenhofer G,Goldstein DS,Walther MM,et al.Biochemical diagnosis of pheochromocytoma:How to distinguish true-from false-positive test results.J Clin Endocrinol Metab,2003,88:2656-2666.
[22]Bravo EL,Tarazi RC,Fouad FM,et al.Clonidine-suppression test:A useful aid in the diagnosis of pheochromocytoma.N Engl J Med,1981,305:623-626.
[23]Zelinka T,Eisenhofer G,Pacak K.Pheochromocytoma as a catecholamine producing tumor:Implications for clinical practice.Stress,2007,10(2):195-203.
[24]Robert TP,Stephen B.Biochemical detection of phaeochromocytoma:why are we continuing to ignore the evidence? Ann Clin Biochem,2008,45:6-10.
[25]JohnH,Ziegler WH,HauriD,et al.Pheochromocytomas:Can malignant potential be predicted? Urology,1999,53:679-683.
[1]Adams JW,Sakata Y,Davis MG,et al.Enhanced Gaq signaling:a common pathway mediates cardiac hypertrophy and apoptotic heart failure.Proc Natl Acad Sci USA,1998,95(17):10140-10145.
[2]Akhter SA,Milano CA,Shotwell KF,et al.Transgenic mice with cardiac overexpression of IB-adrenergic receptors,J Biol Chem,1997,272:21253-21259.
[3]Akhter SA,Luttrell LM,Rockman HA,et al.Targeting the receptor-Gq interface to inhibit in vivo pressure overload myocardial hypertrophy.Science,1998,280:574-577.
[4]Akhter SA,Eckhart AD.In vivo inhibition of elevated myocardial adrenergic receptor kinase activity in hybrid transgenic mice restores normal adrenergic signaling and function.Circulation,1999,100:648-653.
[5]Anker SD,Chau TP,Ponikowski P,et al.Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia.Circulation,1997,96:526-534.
[6]Asai K,Yang GP,Geng YJ,et al.Adrenergic receptor blockade arrests myocyte damage and preserves cardiac function in the transgenic Gs mouse.J Clin Invest,1999,104:551-558.
[7]Baker A J,Redfern CH,Harwood MD,et al.Abnormal contraction caused by expression of Gi coupled receptor in transgenic model of dilated cardiomyopathy.Am J Physiol,2001,280:H1653-H1659.
[8]Bristow MR,Ginsburg R,Minobe W,et al.Decreased catecholamine sensitivity and adrenergic receptor density in failing human hearts.N Engl J Med,1982,307:205-211.
[9]Bristow MR,Herschberger RE.Adrenergic receptor mediated adenylyl cyclase stimulation in non-failing and failing human ventricular myocardium.Mol Pharmacol,1989,35:395-399.
[10]Bristow MR,Minobe W,Raynolds MV,et al.Reduced receptor messenger RNA abundance in the failing human heart.J Clin Invest,1993,92:2737-2745.
[11]Chein KR.Stress pathways and heart failure.Cell,1999,98:555-558.
[12]Choi D-J,Koch WJ,Hunter JJ,et al.Mechanism for adrenergic receptor desensitization in cardiac hypertrophy is increased adrenergic receptor kinase.J Biol Chem,1997,272:17223-17229.
[13]Chu G,Haghighi K,Kranias EG.From mouse to man:understanding heart failure through genetically altered mouse models.J Card Failure,2002,8:S432-S449
[14]Clapham DE,Neer EJ.G protein beta gamma subunits.Annu Rev Pharmacol Toxicol.1997,37:167-203.
[15]Cohn JN,Levine TB,Olivari MT,et al.Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure.N Engl J Med,1984,311:819-823.
[16]Dorn GW Ⅱ,Tepe NM,Lorenz JN,et al.Low and high adrenergic receptors differentially affect cardiac hypertrophy and function in Gaq overexpressing mice.Proc Natl Acad Sci USA,1999,96:6400-6405.
[17]Du X-J,Autelitano DJ,Dilley RJ,et al.02 adrenergic receptor overexpression exacerbates development of heart failure after aortic Stenosis.Circulation,2000,101:71-77.
[18]Woodruff JF.Viral myocarditis:a review.Am J Pathol 1980,101:427-479.
[19]Drory Y,Turetz Y,Hiss Y,et al.Sudden unexpected death in persons less than 40 years of age.Am J Cardiol 1991,68:1388-1392.
[20]Kawai C.From myocarditis to cardiomyopathy:mechanisms of inflammation and cell death.Circulation 1999,99:1091-1100.
[21]Fuster V,Gersh BJ,Giuliani ER,Tajik AJ,Brandenburg RO,Frye RL.The natural history of idiopathic dilated cardiomyopathy.Am J Cardiol 1981,47:525-531.
[22]Feldman AM,McNamara D.Myocarditis.N Engl J Med 2000,343:1388-1398.
[23]Bean B.Antiviral therapy:current concept and practices.Clin.Microbiol 1992,5:146-182.
[24]Zoulim F,Haem J,Ahmed SS,et al.Ribavirin monotherapy in patients with chronic hepatitis C:a retro-spective study of 95 patients.J Viral Hepat 1998,5:193-198.
[25]Weislow OS,Kiser R,Fine DL,Bader J,Shoemaker RH,Boyd MR.New soluble-formazan assay for HIV-1 cytopathic effects:application to highflux screening of synthetic and natural products for AIDS-antiviral activity.J Natl Cancer Inst 1989,81:577-586.
[26]Pauwels R,Balzarini J,Baba M,et al.Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds.J Virol methods 1988,20:309-321.
[27]Logu AD,Loy G,Pellerano ML,Bonsignore L,Schivo ML.Inactivation of HSV-1 and HSV-2 and prevention of cell-to-cell virus spread by Santolina insularis essential oil.Antiviral Res 2000,48:177-185.
[28]Scudiero DA,Shoemaker RH,Paull KD,et al.Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines.Cancer Res 1998,48:4827-4833.
[29]Boulware SL,Bronstein JC,Nordby EC,Weber PC.Identification and characterization of benzothiophene inhibitor of herpes simplex virus type 1 replication which acts at the immediate early stage of infection.Antiviral Res 2001,51:111-125.
[30]Bergelson JM,Modlin JF,Wieland-Alter W,Cunningham JA,Crowell RL,Finberg RW.Clinical coxsackievirus B isolates differ from laboratory strains in their interaction with two cell surface receptors.J Infect Dis 1997,175:697-700.
[31]Muckelbauer JK,Kremer M,Minor I,et al.The structure of coxsackievirus B3 at 3.5 Angstrom resolution.Structure 1995,3:653-667.
[32]He Y,Chipman PR,Howitt J,et al.Interaction of coxsackievirus B3 with the full length coxsackievirus-adenovirus receptor.Nat Struct Biol 2001,8:874-878.
[33]Rossmann MG.The canyon hypothesis.Viral Immunol 1989,2:143-161.
[34]Bergelson JM,Cunningham JA,Droguett G,et al.Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5.Science 1997,275:1320-1323.
[35]Shafren DR,Williams DT,Barry RD.A decay-accelerating factor-binding strain of coxsackievirus B3 requires the coxsackievirus-adenovirus receptor protein to mediate lytic infection of rhabdomyosarcoma cells.J Virol 1997,71:9844-9848.
[36]Pfeffer MA,Braunwald E.Ventricular remodeling after myocardial infarction:experimental observations and clinical implications.Circulation 1990,81:1161-72.
[37]Ho KK,Anderson KM,Kannel WB,Grossman W,Levy D.Survival after the onset of congestive heart failure in Framingham heart study subjects.Circulation 1993,88:107-15.
[38]Redfield MM.Epidemiology and pathophysiology of heart failure.Curr Cardiol Rep 2000,2:179-80.
[39]Edward D.Freis Studies in Hemodynamics and Hypertension.Hypertension 2001,38:1-5.
[40]Frohlich ED.Cardiac hypertrophy in hypertension.N Engl J Med 1987,317:831-833.
[41]Vasan RS,Levy D.The role of hypertension in the pathogenesis of heart failure.A clinical mechanistic overview.Arch Intern Med 1996,156:1789-1796.
[42]Mann DL.Mechanisms and Models in Heart Failure:A Combinatorial Approach Circulation 1999,100:999-1008.
[43]Jessup M,Brozena S.Heart failure.N Engl J Med 2003,348:2007-18.
[44]Iwama H,Amagaya S,Ogihara Y.Effect of shosaikoto,a Japanese and Chinese traditional herbal medical mixture,on the mitogenic activity of lipopolysaccharide:a new pharmacological testing method.J Ethnopharmacol 1987;21(1):45-53
[45]Uneda M,Amagaya S,Ogihara Y Effect of certain herbal medicines on the biotransformation of arachidonic acid:a new pharmacological testing method using serum.J Ethnopharmacol 1988;23(1):91-98
[46]Yutao X,Geru W,Xiaojun B,et al.Mechanical stretch-induced hypertrophy of neonatal rat ventricular myocytes is mediated by beta (1)-integrin-microtubule signaling pathways.Eur J Heart Fail 2006,Jan,8(1):16-22.
[47]Rockman HA,Knowlton KU,Ross J Jr,Chien KR.In vivo murine cardiac hypertrophy:a novel model to identify genetic signaling mechanisms that activate an adaptive physiologic response.Circulation 1993,87 (Suppl.Ⅶ):Ⅶ-14-Ⅶ-21.
[48]Lompre AM,Schwartz K,d'Albis A,Lacombe G,Van Thiem N,Swynghedauw B.Myosin isoenzyme redistribution in chronic heart overload.Nature 1979,282(5734):105-107.
[49]Sealy J,Laragh JH.How to do plasma renin assay.In:Laragh JH,ed.Topics in Hypertension.New York,NY:Yorke Medical Books,1980:244-56.
[50]Dolber PC,Spach MS.Picrosirius red staining of cardiac muscle following phosphomolybdic acid treatment.Stain Technol 1987,62:23-26.
[51]Farrell MH,Foody JM,Krumholz HM.Beta-blockers in heart failure:clinical applications.JAMA 2002,287:890-97.
[52]Nanas JN,Alexopoulos G,Anastasiou-Nana MI,Karidis K,Tirologos A,.Zobolos S.Outcome of patients with congestive heart failure treated with standard versus high doses of enalapril:a Multicenter study.J Am Coll Cardiol 2000,36:2090-95.
[53]Packer M,Poole-Wilson PA,Armstrong PW,et al.Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor,lisinopril,on morbidity and mortality in chronic heart failure.Circulation 1999,100:2312-18.
[54]McMurray J,Pfeffer MA.New Therapeutic Options in Congestive Heart Failure.Circulation 2002,105:2099-06.
[55]Eugene Braunwald,Michael R.Bristow.Congestive Heart Failure:Fifty Years of Progress.Circulation 2000,102:Ⅳ-14-Ⅳ-23.
[56]Grossman W,Jones D,McLaurin LP.Wall stress and patterns of hypertrophy in the human left ventricle.J Clin Invest 1974,56:56-64.
[57]Gerdes AM,Kellerman SE,Moore JA,Muffly KE,Clark LC,Reaves PY,Malec KB,McKeown PP,Schocken DD.Structural remodeling of cardiac myocytes from patients with chronic ischemic heart disease.Circulation 1992,86:426-430.
[1]Abdel-Aleem S,El-Merzanai MM,Sayed-Ahmed M,et aL Acute and chronic effects of doxorubicin on fatty acid oxidation in isolated cardiac myocytes.Journal of Molecular and Cellular Cardiology,1997,29:789-797.
[2]Adams MJ,Lipshultz,SE.Pathophysiology of anthracycline-and radiation-associated cardiomyopathies:implications for screening and prevention.Pediatric Blood and Cancer,2005,44:600-606.
[3]Alderton PM,Gross J,Green MD.Comparative study of doxorubicin,mitoxantrone,and epirubicin in combination with 1CRF-187 (ADR-529)in a chronic cardiotoxicity animal model.Cancer Research,1992,52:194-201.
[4]Anderlini P,Benjamin RS,Wong FC,et al.Idarubicin cardiotoxicity:a retrospective study in acutemyeloid leukemia and myelodysplasia.Journal of Clinical Oncology,1995,13:2827-2834.
[5]Antunes,LM,Takahashi,CS.Protection and induction of chromosomal damage by vitamin C in human lymphocyte cultures.Teratogenesis,Carcinogenesis,and Mutagenesis,1999,19:53-59.
[6]Arai M,Yoguchi A,Takizawa T,et al.Mechanism of doxorubicin-induced inhibition of sarcoplasmatic reticulum Ca2+-ATPase gene transcription.Circulation Research,2000,86:8-14.
[7]Arola OJ,Saraste A,Pulkki K,et al.Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis.Cancer Research,2000,60:1789-1792.
[8]Arrick BA,Nathan CF,Griffith OW,et al.Glutathione depletion sensitizes tumor cells to oxidative cytolysis.The Journal of Biological Chemistry,1982,257:1231-1237.
[9]Batist G,Ramakrishnan G,Rao CS,et al.Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized,multicenter trial of metastatic breast cancer.Journal of Clinical Oncology,2001,19:1444-1454.
[10]Benjamin RS.Rationale for the use of mitoxantrone in the older patient:cardiac toxicity.Seminars of Oncology,1995,22:11-13.
[11]Bhanumathi P,Saleesh EB,Vasudevan DM.Creatinine phosphokinase and cardiotoxicity in doxorubicin chemotherapy and its modification by WR-1065.Biochemical Archives,1992,8:335-338.
[12]Bieber,LL.CarnitinE Annual Review of Biochemistry,1988,57:261-283.
[13]Bleyer W.The impact of childhood cancer on the US and the world.CA:A Cancer Journal for Clinicians,1990,40:355-367.
[14]Boucher F,Coudray C,Tirard V,et al.Oral selenium supplementation in rats reduces cardiac toxicity of doxorubicin during ischemia and reperfusioN Nutrition,1995,11:708-711.
[15]Bozkurt B,Torre-Amione G,Warren MS,et al.Results of targeted antitumor necrosis factor therapy with etanercept (ENBREL)in patients with advanced heart failure.Circulation,2001,103:1044-1047.
[16]Breed JG,Zimmerman AN,Dormans JA,et al.Failure of the antioxidant vitamin E to protect against adriamycininduced cardiotoxicity in the rabbit.Cancer Research,1980,40:2033-2038.
[17]Bristow MR.Mechanisms of action of beta-blocking agents in heart failure.American Journal of Cardiology,1997,80:26L-40L
[18]Bruns LA,Chrisant MK,Lamour JM,et al.Carvedilol as therapy in pediatric heart failure:an initial multicenter experience.Journal of Pediatrics,2001,138:505-511.
[19]Calabro-Jones PM,Aguilera JA,Ward JF,et al.Uptake of WR-2721 derivatives by cells in cultures:identification of the transported form of the drug.Cancer Research,1988,48:3634.
[20]Capizzi R,Oster W.Protection of normal tissue from the cytotoxic effects of chemotherapy and radiation by amifostine:clinical experiences.European Journal of Cancer,1995,31:S8-13.
[21]Carella AM,Berman E,Maraone MP,et al.Idarubicin in the treatment of acute leukemiaS An overview of preclinical and clinical studies.Haematologica,1990,75:159-169.
[22]Carew TE,Schwenke DC,Steinberg D.Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect:evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit.Proceedings of the National Academy of Sciences of the United States of America,1987,84:7725-7729.
[23]Childs AC,Phaneuf SL,Dirks AJ,et al.Doxorubicin treatment in vivo causes cytochrome c release and cardiomyocyte apoptosis,as well as increased mitochondrial efficiency,superoxide dismutase activity,and Bcl-2:Bax ratio.Cancer Research,2002,62:4592-4598.
[24]Ciaccio M,Valenza M,Tesoriere L,et al.Vitamin A inhibits doxorubicin-induced membrane lipid peroxidation in rat tissues in vivo.Archives of Biochemistry and Biophysics,1993,302:103-108.
[25]Ciaccio M,Tesoriere L,Pintaudi AM,et al.Vitamin A preserves the cytotoxic activity of doxorubicin while counteracting its peroxidative effects in human leukemic cells in vitro.Biochemistry and Molecular Biology International,1994,34:329-335.
[26]Cortes EP,Gupta M,Chou C,et al.Doxorubicin cardiotoxicity:early detection by systolic time interval and possible prevention by coenzyme Q10.Cancer Treatment Reports,1978,62:887-891.
[27]Cottin Y,Touzery C,Dalloz F,et al.Comparison of epirubicin and doxorubicin cardiotoxicity induced by low doses:evolution of the diastolic and systolic parameters studies by radionuclide angiography.Clinical Cardiology,1998,21:665-670.
[28]Coudray C,Mouhieddine S,Richard MJ,et al.Effects of doxorubicin on chronic cardiotoxicity in selenium-deficient rats.Basic Research in Cardiology,1992,87:173-183.
[29]Creutzig U,Ritter J,Zimmermann M,et al.Idarubicin improves blast cell clearance during induction therapy in children with AML:results of study AML-BFM 93.AML-BFM Study GrouP Leukemia,2001,15:348-354.
[30]Cvetkovic RS,Scott LJR.Dexrazoxane:a review of its use for cardioprotection during anthracycline chemotherapy.Drugs,2005,65:1005-1024.
[31]D'Aquino M,Dunster C,Willson RL.Vitamin A and glutathione-mediated free radical damage:competing reactions with polyunsaturated fatty acids and vitamin c.Biochemical and Biophysical Research Communications,1989,161:1199-1203.
[32]Danelisen I,Palace V,Lou H,et al.Maintenance of myocardial levels of vitamin A in heart failure due to doxorubicin.Journal of Molecular and Cellular Cardiology,2002,34:789-795.
[33]De Flora S,Bennicelli C,Serra D,et al.Role of glutathione and N-acetylcysteine on the mutagenicity and carcinogenesis.In:Absorption and Utilization of Amino Acids (eD by M Friedman),VoL Ⅲ,1989,19-53.CRC Press,Boca Raton,USA
[34]De Leonardis V,Neri B,Bacalli S,et al.Reduction of cardiac toxicity of anthracyclines by L-carnitine:preliminary overview of clinical data.International Journal of Clinical Pharmacology Research,1985,2:137-142.
[35]De Leonardis V,De Scalzi M,Neri B,et al.Echocardiography assessment of anthracycline cardiotoxicity during different therapeutic regimens.International Journal of Clinical Pharmacology Research,1987,7:307-311.
[36]Deswal A,Bozkurt B,Seta Y,et al.Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel,etanercept)in patients with advanced heart failure.Circulation,1999,99:3224-3226.
[37]Didi M,Didcock E,Davies HA,et al.High incidence of obesity in young adults after treatment of acute lymphoblastic leukemia in childhood.Journal of Pediatrics,1995,127:63-67.
[38]Doba T,Burton GW,Ingold KU.Antioxidant and co-antioxidant activity of vitamin C The effect of vitamin C,either alone or in the presence of vitamin E or a water-soluble vitamin E analogue,upon the peroxidation of aqueous multilamellar phospholipid liposomes.Biochemica and Biophysica Acta,1985,835:298-303.
[39]Doroshow JH,Locker GY,Meyers CE.Enzymatic defenses of the mouse heart against reactive oxygen metabolites Journal of Clinical Investigation,65,128-135.Dorr,RT & Lagel,KE (1994)Anthracycline cardioprotection by amifostine (WR-2721)and its active metabolite (WR-1065)in vitro.Proceedings of the American Society of Clinical Oncology,1980,13:435.
[40]Dorr RT,Shipp NG,Lee KM.Comparison of cytotoxicity in heart cells and tumor cells exposed to DNA intercalating agents in vitro.Anti-Cancer Drugs,1991,2:27-33.
[41]Dragojevic-Simic VM,Dobric SL,Bokonjic DR,et al.Amifostine protection against doxorubicin cardiotoxicity in ratS Anti-Cancer Drugs,2004,15:169-178.
[42]Faber M,Coudray C,Hida H,et al.Lipid peroxidation products,and vitamin and trace element status in patients with cancer before and after chemotherapy,including doxorubiciN A preliminary study.Biological Trace Element Research,1995,47:117-123.
[43]Fassas A,Buffels R,Anagnostopoulos A,et al.Safety and early efficacy assessment of liposomal daunorubicin (DaunoXome)in adults with refractory or relapsed acute myeloblastic leukemia:a phase I-1I studY British Journal of Haematology,2002,116:308-315.
[44]Fazio S,Sabatini D,Capaldo B,et al.A preliminary study of growth hormone in the treatment of dilated cardiomyopathy.The New England Journal of Medicine,1996,334:809-814.
[45]Fazio S,Palmieri EA,Ferravante B,et al.Doxorubicin-induced cardiomyopathy treated with carvedilol.Clinical Cardiology,1998,21:777-779.
[46]Ferrari R,Ceconi C,Curello S.Oxygen free radicals and myocardial damage:protective role of thiol-containing agents.American Journal of Medicine,1991,91:95S-105S
[47]Ferrari R,Bachetti T,Confortini R,et al.Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure.Circulation,1995,92:1479-1486.
[48]Feuerstein GZ,Ruffolo RR.Carvedilol,a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection.European Heart Journal,1995,16:38-42.
[49]Fisher PW,Salloum R,Das A,et al.Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity.Circulation,2005,111:1601-1610.
[50]Folkers K,Choe JY,Combs AB.Rescue by coenzyme Q10 from electrocardiographic abnormalities caused by the toxicity of doxorubicin in the rat.Proceedings of the National Academy of Sciences of the United States of America,1978,75:5178-5180.
[51]Folkers K,Brown R,Judy WV,et al.Survival of cancer patients on therapy with coenzyme Q10.Biochemical and Biophysical Research Communications,1993,192:241-245.
[52]Frei,B.Reactive oxygen species and antioxidant vitamins:mechanisms of action.American Journal of Medicine,1994,97:5S-13S
[53]Frishman WH.CarvediloL Drug Therapy,1998,24:1759-1765.
[54]Gabizon AA.Liposomal anthracyclines.Hematology/Oncology Clinics of North America,1994,8:431-450.
[55]Ganzina F.4 (?)-epi-doxorubicin,a new analogue of doxorubicin:a preliminary overview of preclinical and clinical data.Cancer Treatment Reviews,1983,10:1-22.
[56]Ganzina F,Di Pietro N,Magni O.Clinical toxicity of 4 (?)-epi-doxorubicin (epirubicin).Tumori,1985,71:233-240.
[57]Gatta G,Capocaccia R,Coleman MP,et al.Childhood cancer survival in Europe and the United States.Cancer,2002,95:1767-1772.
[58]Geetha A,Catherine J,Shyamala Devi CS.Effect of alphatocopherol on the microsomal lipid peroxidation induced by doxorubicin:influence of ascorbic acid.Indian Journal of Physiological Pharmacology,1989,33:53-58.
[59]Gewirtz DA.A Critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics doxorubicin and daunorubicin.Biochemical Pharmacology,1999,57:727-741.
[60]Gianni L,Zweier J,Levy A,et al.Characterization of the cycle of iron-mediated electron transfer from doxorubicin to molecular oxygen.Journal of Biological Chemistry,1985,259:6056-6058.
[61]Giantris A,Abdurrahman L,Hinkle A,et al.Anthracycline-induced cardiotoxicity in children and young adults.Critical Reviews in Oncology/Hematology,1998,27:53-68.
[62]Gill PS,Wernz J,Scadden DT.Randomized phase 111 trial of liposomal daunorubicin versus doxorubicin,bleomycin,and vincristine in AlDS-related Kaposi's sarcoma.Journal of Clinical Oncology,1996,14:2353-2364.
[63]Glover D,Glick JH,Weiler C,et al.Phase Ⅰ/Ⅱ trials of WR-2721 and cis-platinum.International Journal of Radiation Oncology Biology Physics,1986,12:1509-1512.
[64]Goldhaber SB.Trace element risk assessment:essentiality vS toxicity.Regulatory Toxicology and Pharmacology,2003,38:232-242.
[65]Goormaghtigh E,Huart P,Praet M,et al.Structure of the doxorubicin-cardiolipin complex role in mitochondrial toxicity.Biophysical Chemistry,1990,35:247-257.
[66]Green DM,Hyland A,Chung CS,et al.Cancer and cardiac mortality among 15-year survivors of cancer diagnosed during childhood or adolescence.Journal of Clinical Oncology,1999,17,3207-3215.
[67]Green DM,Grigoriev YA,Nan B,et al.Congestive heart failure after treatment for Wilms' tumor:a report from the National Wilms' Tumor Study Group.Journal of Clinical Oncology,2001,19:1926-1934.
[68]Grenier MA,Lipshultz SE.Epidemiology of anthracycline cardiotoxicity in children and adults.Seminars in Oncology,1998,25:72-85.
[69]Halliwell B.Vitamin C:antioxidant or pro-oxidant in vivo.Free Radical Research,1996,25: 439-454.
[70]Hailiwell B,Gutteridge JMC.Antioxidant protection by low-molecular-mass agents:compounds derived from the dieT In:Free Radicals in Biology and Medicine (eD by B Hailiwell & JMC Gutteridge),1999,200-217.Oxford University Press,New York,USA
[71]Haq MM,Legha SS,Choksi J,et al.Doxorubicin-induced congestive heart failure in adults.Cancer,1985,56:1361-1365.
[72]Harris L,Batist G,Belt R,et al.Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma.Cancer,2002,94:25-36.
[73]Hasinoff BB.The interaction of the cardioprotective agent ICRF-187 [+)-l,2-bis(3,5-dioxopiperazinyl-l-yL)propane);its hydrolysis product (ICRF-198);and other chelating agents with the Fe(Ⅲ)and Cu(Ⅱ)complexes of doxorubicin.Agents Actions,1989,26:378-385.
[74]Heidenreich PA,Lee TT,Massie BM.Effect of betablockade on mortality in patients with heart failure:a meta-analysis of randomized clinical trials.Journal of American College of Cardiology,1997,30:27-34.
[75]Herman EH,Ferrans VJ.Reduction of chronic doxorubicin cardiotoxicity in dogs by pretreatment with (+/))-l,2-bis (3,5-dioxopipreazine-l-yl)propane (ICRF-187).Cancer Research,1981,41:3436-3440.
[76]Herman EH,Ferrans VJ,Young RS,et al.Effect of pretreatment with ICRF-187 on the total cumulative dose of doxorubicin tolerated by beagle dogs.Cancer Research,1988,48:6918-6925.
[77]Herman EH,Zhang J,Hasinoff BB,et al.Comparison of the structural changes induced by doxorubicin and mitoxantrone in the heart,kidney and intestine and characterization of the Fe(Ⅲ)-mitoxantrone complex.Molecular and Cellular Cardiology,1997a,29:2415-2430.
[78]Herman EH,Zhang J,Hasinoff BB,et al.Comparison of the protective effects against chronic doxorubicin cardiotoxicity and the rates of iron (Ⅲ)displacement reactions of ICRF-187 and other bisdiketopiperazines.Cancer Chemotherapy and Pharmacology,1997b,40:400-408.
[79]Herman EH,Zhang J,Chadwick DP,et al.Comparison of the protective effects of amifostine and dexrazoxane against the toxicity of doxorubicin in spontaneously hypertensive rats.Cancer Chemotherapy and Pharmacology,2000,45:329-334.
[80]Herman EH,Zhang J,Rifai N,et al.The use of serum levels of cardiac troponinTto compare the protective activity of dexrazoxane against doxorubicin-and mitoxantrone-induced cardiotoxicity.Cancer Chemotherapy and Pharmacology,2001,48:297-304.
[81]Hinkle AS,Proukou CB,Deshpande SS,et al.Cardiotoxicity caused by chemotherapY In:Late Effects of Childhood Cancer (eD by WHB Wallace & DM Green),2004a,85-100.Edward Arnold,New York,USA
[82]Hinkle AS,Proukou C,French CA,et al.A clinicbased,comprehensive care model for studying late effects in longterm survivors of pediatric illnesses.Pediatrics,2004b,113:1141-1145.
[83]Hortobagyi GN,Frye D,Buzdar AU,et al.Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma.Cancer,1989,63:37-45.
[84]larussi D,Auricchio U,Agretto A,et al.Protective effect of coenzyme Q10 on anthracyclines cardiotoxicity:control study in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma.Molecular Aspects of Medicine,1994,15:207-212.
[85]lliskovic N,Singal PK.Lipid lowering:an important factor in preventing doxorubicin-induced heart failure.American Journal of Pathology,1997,150:727-734.
[86]lliskovic N,Hasinoff BB,Malisza KL,et al.Mechanisms of beneficial effects of probucol in doxorubicin cardiomyopathy.Molecular and Cellular Biochemistry,1999,196:43-49.
[87]Institute of Medicine,Food and Nutrition Board (2001)Dietary Reference Intakes:Vitamin A,Vitamin K,Arsenic,Boron,Chromium,Copper,Iodine,Iron,Manganese,Molybdenum,Nickel,Silicon,Vanadium,and Zinc.National Academy Press,Washington,DC,USA
[88]Isgaard J,Bergh CH,Caidahl K,et al.A placebo-controlled study of growth hormone in patients with congestive heart failure.European Heart Journal,1998,19:1704-1711.
[89]Iwamoto Y,Yamagami T,Folkers K.Deficiency of coen2yme Q10 in hypertensive rats and reduction of deficiency by treatment with coenzyme Q10.Biochemical and Biophysical Research Communications,1974,58:743-748.
[90]Jeyaseelan R,Poizat C,Wu HY,et al.Molecular mechanisms of doxorubicin-induced cardiomyopathY Selective suppression of Reiske iron-sulfur protein,ADP/ATP translocase,and phosphofructokinase genes is associated with ATP depletion in rat cardiomyocytes.Journal of Biological Chemistry,1997,272:5828-5832.
[91]Kishi T,Folkers K.Prevention by coenzyme Q10 of the inhibition by doxorubicin of coenzyme Q10-enzymes.Cancer Treatment Reports,1976,60:223-224.
[92]Klein S,Burke LE,Bray GA,et al.Clinical implications of obesity with specific focus on cardiovascular disease:a statement for professionals from the American Heart Association Council on Nutrition,Physical Activity,and Metabolism:endorsed by the American College of Cardiology Foundation.Circulation,2004,110:2952-2967.
[93]Kremer LCM,van Dalen EC,Offringa M,et al.AnthracycHne-induced clinical heart failure in a cohort of 607 children:long-term follow-up study.Journal of Clinical Oncology,2001,19:191-196.
[94]Kremer LCM,van der Pal HJ,Offringa M,et al.Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children:a systematic review.Annals of Oncology,2002,13:819-829.
[95]Kn'nsky NI.Mechanisms of carotenoids in biological systems.Annual Review of Nutrition,1993,13:561-587.
[96]Krischer JP,Epstein S,Cuthbertson DD,et al.Clinical cardiotoxicity following anthracycline treatment for childhood cancer:the Pediatric Oncology Group Experience.Journal of Clinical Oncology,1997,15:1544-1552.
[97]Kurbacher CM,Wagner U,Kolster B,et al.Ascorbic acid (vitamin C)improves the antineoplastic activity of doxorubicin,cisplatin,and paclitaxel in human breast carcinoma cells in vitro.Cancer Letters,1996,103:183-189.
[98]Kuzuya M,Kuzuya F.Probucol as an antioxidant and antiatherogenic drug.Free Radical Biology and Medicine,1993,14:67-77.
[99]Lahtinen R,Kuikka J,Nousiainene T,et al.Cardiotoxicity of epirubicin and doxorubicin:a double-blind randomized study.European Journal of Haematology,1991,46:301-305.
[100]Lebrecht DMS,Setzer B,Ketelsen UP,et al.Time-dependant and tissue-specific accumulation of mtDNA and respiratory chain defects in chronic doxorubicin cardiomyopathy.Circulation,2003,108:2423-2429.
[101]Lechat P,Packer M,Chalon S,et al.Clinical effects of beta-adrenergic blockade in chronic heart failure:a meta-analysis of double-blind,placebo-controlled,randomized trials.Circulation,1998,98:1184-1191.
[102]Lefrak EA,Pitha J,Rosenheim S,et al.A clinicopathologic analysis of doxorubicin cardiotoxicity.Cancer,1973,32:302-314.
[103]Legha SS,Benjamin RS,Mackay B,et al.Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion.Annals of Internal Medicine,1982,96:133-139.
[104]Levitt GA,Dorup I,Sorensen K,et al.Does anthracycline administration by infusion in children affect late cardiotoxicity.British Journal of Haematology,2004,124:463-468.
[105]Li T,Singal PK.Doxorubicin-induced early changes in myocardial antioxidant enzymes and their modulation by probucol.Circulation,2000,102:2105-2110.
[106]Li T,Danelisen I,Bello'-Klein A,et al.Effects of probucol on changes of antioxidant enzymes in doxorubicin-induced cardiomyopathy in rats.Cardiovascular Research,2000,46:523-530.
[107]Lipshultz SE,Colan SD,Gelber RD,et al.Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood.The New England Journal of Medicine,1991,324:808-815.
[108]Lipshultz SE,Lipsitz SR,Mone SM,et al.Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer.The New England Journal of Medicine,1995,332:1556-1738.
[109]Lipshultz SE,Giantris AL,Lipsitz SR,et al.Doxorubicin administration by continuous infusion is not cardioprotective:the Dana-Farber 91-01 acute lymphoblastic leukemia protocol.Journal of Clinical Oncology,2002a,20:1677-1682.
[110]Lipshultz SE,Lipsitz SR,Sallan SE,et al.Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer.Journal of Clinical Oncology,2002b,20:4517-4522.
[111]Lipshultz SE,Rifai N,Dalton VM,et al.The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia.The New England Journal of Medicine,2004a,351:145-153.
[112]Lipshultz SE,Colan SD.Cardiovascular trials in longterm survivors of childhood cancer.Journal of Clinical Oncology,2004b,22:769-773.
[113]Lipshultz SE,Lipsitz SR,Sallen SE,et al.Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia.Journal of Clinical Oncology,2005a,23:2629-2636.
[114]Lipshultz SE,Vlach SA,Lipsitz SR,et al.Cardiac changes associated with growth hormone therapy among children treated with anthracyclines.Pediatrics,2005b,115:1613-1622.
[115]Livrea MA,Tesoriere L,Bongiorno A,et al.Contribution of vitamin A to the oxidation resistance of human low density lipoproteins.Free Radical Biology and Medicine,1995,18:401-409.
[116]Lopez M,Vici P,Di Lauro L,et al.Randomized prospective clinical trial to evaluate cardio-protection of dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas.Journal of Clinical Oncology,1998,16:86-92.
[117]Lu J,Jiang C,Kaeck M,et al.Cellular and metabolic effects of triphenylselenonium chloride in a mammary cell culture model.Carcinogenesis,1995,16:513-517.
[118]Matsuda A,Kimura M,Itokawa Y.Influence of selenium deficiency on the acute cardiotoxicity of doxorubicin in rats.Biological Trace Element Research,1997,57:157-167.
[119]Matsui H,Morishima 1,Numaguchi Y,et al.Protective effects of carvedilol against doxorubicin-induced cardiomyopathy in rats.Life Sciences,1999,65:1265-1274.
[120]Meister A.Selective modification of glutathione metabolism.Science,1983,220:472-477.
[121]Mertens AC,Yasui Y,Neglia JP,et al.Late mortality experience in five-year survivors of childhood and adolescent cancer:the Childhood Cancer Survivor Study.Journal of Clinical Oncology,2001,19:3163-3172.
[122]Meyers CE,McGuire WP,Liss RH,et al.Adriamycin:the role of lipid peroxidation in cardiac toxicity and tumor response.Science,1977,197:165-167.
[123]Miller TL,Horgan S,Lipshultz SE.Exercise rehabilitation of pediatric patients with cardiovascular diseasE Progress in Pediatric Cardiology,2005,20:27-37.
[124]Mohamed HE,El-Swefy SE,Hagar HH.The protective effect of glutathione administration on doxorubicin-induced acute cardiac toxicity in rats.Pharmacological Research,2000,42:115-121.
[125]Mo'ller TR,Garwicz S,Barlow L,et al.Decreasing late mortality among five-year survivors of cancer in childhood and adolescence:a population-based study in the Nordic countries.Journal of Clinical Oncology,2001,19:3173-3181.
[126]Money-Kyrle JF,Bates F,Ready J,et al.Liposomal daunorubicin in advanced Kaposi's sarcoma:a phase Ⅱ study.Clinical Oncology (Royal College of Radiologists),1993,5:367-371.
[127]Moran AM,Colan SD,Majzoub JA,et al.Exogenous growth hormone:a new therapy for dilated cardiomyopathy.Progress in Pediatric Cardiology,2000,12:125-132.
[128]Myers CE,Bonow R,Palmeri S,et al.A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine.Seminars in Oncology,1983,10:53-55.
[129]Nazeyrollas P,Frances C,Prevost A,et al.Efficiency of amifostine as a protection against doxorubicin toxicity in rats during a 12-day treatment.Anticancer Research,2003,23:405-409.
[130]Noguchi N,Nishino K,Niki,E.Antioxidant action of the antihypertensive drug,carvedilol,against lipid peroxidation.Biochemical Pharmacology,2000,59:1069-1076.
[131]Nysom K,Colan DC,Lipshultz SE.Late cardiotoxicity following anthracycline therapy for childhood cancer.Progress in Pediatric Cardiology,1998a,8:121-138.
[132]Nysom K,Holm K,Lipsitz SR,et al.Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia.Journal of Clinical Oncology,1998b,2:545-550.
[133]O'Brien ME,Wigler N,Inbar M,et al.Reduced cardiotoxicity and comparable efficacy in a phase Ⅲ trial of pegylated liposomal doxorubicin HC1 (CAELYX/Doxil)versus conventional doxorubicin for first-line treatment of metastatic breast cancer.Annals of Oncology,2004,15:440-449.
[134]O'Byrne KJ,Thomas AL,Sharma RA,et al.A phase I dose-escalating study of DaunoXome,liposomal daunorubicin,in metastatic breast cancer.British Journal of Cancer,2002,87:15-20.
[135]Okuma K,Furuta 1,Ota K.Protective effect of coenzyme Q10 in cardiotoxicity induced by doxorubicin.Gan To Kagaku Ryoho,1984,11:502-508.
[136]Olson R,Mushlin P.Doxorubicin cardiotoxicity:analysis of prevailing hypothesis.FASEB Journal,1990,4:3076-3086.
[137]Osterziel KJ,Strohm O,Schuler J,et al.Randomized,double-blind,placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy.The Lancet,1998,351:1233-1237.
[138]Perego P,Corna E,De Cesare M,et al.Role of apoptosis and apoptosisrelated genes in cellular response and antitumor efficacy of anthracyclines.Current Medicinal Chemistry,2001,8:31-37.
[139]Perez DJ,Harvey VJ,Robinson BA,et al.A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer.Journal of Clinical Oncology,1991,9:2148-2152.
[140]Perrot A,Ranke MB,Dietz R,et al.Growth hormone treatment in dilated cardiomyopathy.Journal of Cardiac Surgery,2001,16:127-131.
[141]Pfeffer MA,Braunwald E,Moye LA,et al.Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction:results of the survival and ventricular enlargement trial-the SAVE Investigators.The New England Journal of Medicine,1992,327:669-677.
[142]Platel D,Pouna P,Bonoron-Adele S,et al.Comparative cardiotoxicity of idarubicin and doxorubicin using the isolated perfused rat heart model.Anti-Cancer Drugs,1999,10:671-676.
[143]Quiles JL,Huertas JR,Battino M,et al.Antioxidant nutrients and doxorubicin toxicity.Toxicology,2002,180:79-95.
[144]Redfield MM,Gersh BJ,Bailey KR,et al.Natural history of incidentally discovered asymptomatic idiopathic dilated cardiomyopathy.American Journal of Cardiology,1994,74:737-739.
[145]Rodvold KA,Rushing DA,Tewksbury DA.Doxorubicin clearance in the obese,Journal of Clinical Oncology,1988,6:1321-1327.
[146]Ryberg M,Nielsen D,Skovsgaard T,et al.Epirubicin cardiotoxicity:an analysis of 469 patients with metastatic breast cancer.Journal of Clinical Oncology,1998,16:3502-3508.
[147]Safra T.Cardiac safety of liposomal anthracyclines.The Oncologist,2003,8:17-24.
[148]Sallan SE,Lipshultz SE.Wise up:don't do it without protectioN Pediatric Blood and Cancer,in press Sayed-Ahmed,MM,Salman,TM,Gaballah,HE,Abou El Naga,SA,Nicolai,R & Calvani,M (2001)Propionyl-L-carnitine as protector against doxorubicin-induced cardiomyopathy.Pharmacological Research,2005,43:513-520.
[149]Schuchter LM,Hensley ML,Meropol NJ,et al.Update of recommendations for the use of chemotherapy and radiotherapy protectants:clinical practice guidelines of the American Society of Clinical Oncology.Journal of Clinical Oncology,2002,20:2895-2903.
[150]Seta Y,Shan K,Bozkurt B,et al.Basic mechanisms in heart failure:the cytokine hypothesis.Journal of Cardiac Failure,1996,2:243-249.
[151]Shaddy RE,Tani LY,Gidding SS,et al.Beta-blocker treatment of dilated cardiomyopathy with congestive heart failure in children:a multiinstirutional experience.Journal of Heart and Lung Transplantation,1999,18:269-274.
[152]Shapira J,Gotfried M,Lishner M,et al.Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen:a prospective randomized evaluation.Cancer,1990,65:870-873.
[153]Shimpo K,Nagatsu T,Yamada K,et al.Ascorbic acid and doxorubicin toxicity.American Journal of Clinical Nutrition,1991,54:1298S-1301S
[154]Silber JH,Cnaan A,Clark BJ,et al.Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines.Journal of Clinical Oncology,2004,22:820-828.
[155]Simbre VC Ⅱ,Adams MJ,Deshpande SS,et al.Cardiomyopathy caused by antineoplastic therapies.Current Treatment Options in Cardiovascular Medicine,2001,3:493-505.
[156]Simbre VC Ⅱ,Duffy SA,Dadlani GH,et al.Cardiotoxicity of cancer chemotherapy:implications for children.Pediatric Drugs,2005,7:187-202.
[157]Singal PK,Iliskovic N.Doxorubicin-induced cardiomyopathy.The New England Journal of Medicine,1998,339:900-905.
[158]Singal PK,Deally CM,Weinberg LE.Subcellular effects of doxorubicin in the heart.A concise revieW Journal of Molecular and Cellular Cardiology,1987,19:817-828.
[159]Siveski-Iliskovic N,Hill M,Chow DA,et al.Probucol protects against doxorubicin cardiomyopathy without interfering with its antitumor effect.Circulation,1995,91:10-15.
[160]Skudicky D,Sliwa K,Bergemann A,et al.Reduction in Fas/Apo-1 plasma concentrations correlates with improvement in left ventricular function in patients with idiopathic dilated cardiomyopathy treated with Pentoxifylline.Heart,2000,84:438-441.
[161]Skudicky D,Bergemann A,Sliwa K,et al.Beneficial effects of pentoxifylline in patients with idiopathic dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitors and carvedilol:results of a randomized study.Circulation,2001,103:1083-1088.
[162]Slamon D.Pegram M.Rationale for trastuzumab (Herceptin)in adjuvant breast cancer trials.Seminars in Oncology,2001,28:13-19.
[163]Sliwa K,Woodiwiss A,Candy G,et al.Effects of pentoxifylline on cytokine profiles and left ventricular performance in patients with decompensated congestive heart failure secondary to idiopathic dilated cardiomyopathy.American Journal of Cardiology,2002,90:1118-1122.
[164]Sorensen K,Levitt G,Sebag Montefiore D,et al.Cardiac function in Wilms' tumor survivors.Journal of Clinical Oncology,1995,13:1546-1556.
[165]Sorensen K,Levitt G,Bull C,et al.Anthracycline dose in childhood acute lymphoblastic leukemia:issues of early survival versus late cardiotoxicity.Journal of Clinical Oncology,1997,15:61-68.
[166]Sorensen K,Levitt GA,Bull C,et al.Late anthracycline cardiotoxicity after childhood cancer.Cancer,2003,97:1991-1998.
[167]Spallarossa P,Garibaldi S,Altieri P,et al.Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro.Journal of Molecular and Cellular Cardiology,2004,37:837-846.
[168]Speyer JL,Green MD,Zeleniuch-Jacquotte A,et al.ICRF-187 permits longer treatment with doxorubicin in women with breast cancer.Journal of Clinical Oncology,1992,10:117-127.
[169]Steinherz LJ,Steinherz PG,Tan CT,et al.Cardiac toxicity 4 to 20 years after completing anthracycline therapy.JAMA,1991,266:1672-1677.
[170]Sugino K,Dohi K,Yamada K,et al.The role of lipid peroxidation in endotoxin-induced hepatic damage and the protective effect of antioxidants.Surgery,1987,101:746-752.
[171]Suttorp N,Toepfer W,Roka,L.Antioxidant defense mechanisms of endothelial cells:glutathione redox cycle versus catalase.American Journal of Physiology,1986,251:671-680.
[172]Swain SM,Whaley FS,Gerber MC,et al.Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.Journal of Clinical Oncology,1997a,15:1318-1332.
[173]Swain SM,Whaley FS,Gerber MC,et al.Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy.Journal of Clinical Oncology,1997b,15:1333-1340.
[174]Swain SM,Whaley FS,Ewer MS.Congestive heart failure in patients treated with doxorubicin:a retrospective analysis of three trials Cancer,2003,97:2869-2879.
[175]Takabe W,Kodama T,Hamakubo T,et al.Anti-atherogenic antioxidants regulate the expression and function of protea-some alpha-type subunits in human endothelial cells.Journal of Biological Chemistry,2001,44:40497-40501.
[176]Tardi PG,Boman NL,Cullis PR.Liposomal doxorubicin.Journal of Drug Targeting,1996,4:129-140.
[177]The American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure)Guidelines for the evaluation and management of heart failurE Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure).Circulation,1995,92:2764-2784.
[178]The SOLVD Investigators.Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.The New England Journal of Medicine,1991,325:293-302.
[179]The SOLVD Investigators.Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions.The New England Journal of Medicine,1992,327:685-691.
[180]The SOLVD Investigators.Effects of long-term enalapril therapy on left ventricular diastolic properties in patients with depressed ejection fraction.Circulation,1993,88:481-491.
[181]Thuesen L,Christiansen JS,Sorensen KE,et al.P Increased myocardial contractility following growth hormone administration in normal man.An echocardiographic studY Danish Medical Bulletin,1988,35:193-196.
[182]Torre-Amione G,Kapadia S,Benedict CR,et al.Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction:a report from the studies of left ventricular dysfunction (SOLVD).Journal of the American College of Cardiology,1996,27:1201-1206.
[183]Traber MG,Packer L.Vitamin E:beyond antioxidant function.American Journal of Clinical Nutrition,1995,62:1501-1509.
[184]Unverferth DV,Unverferth BJ,Balcerzak SP,et al.Cardiac evaluation of mitoxantrone.Cancer Treatment Reports,1983,67:343-350.
[185]Van Vleet JF,Greenwood L,Ferrans VJ,et al.Effect of selenium-vitamin E on doxorubicin-induced cardiomyopathy in rabbits.American Journal of Veterinary Research,1978,39:997-1010.
[186]Van Vleet JF,Ferrans VJ,Weirich WE.Cardiac disease induced by chronic doxorubicin administration in dogs and an evaluation of vitamin E and selenium as cardioprotectants.American Journal of Pathology,1980,99:13-42.
[187]Venturini M,Michelotti A,Del Mastro L,et al.Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer.Journal of Clinical Oncology,1996,14:3112-3120.
[188]Volterrani M,Desenzani P,Lorusso R,et al.Haemodynamic effects of intravenous growth hormone in congestive heart failure.The Lancet,1997,349:1067-1068.